<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">World J Gastroenterol</journal-id>
      <journal-id journal-id-type="iso-abbrev">World J. Gastroenterol</journal-id>
      <journal-id journal-id-type="publisher-id">WJG</journal-id>
      <journal-title-group>
        <journal-title>World Journal of Gastroenterology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1007-9327</issn>
      <issn pub-type="epub">2219-2840</issn>
      <publisher>
        <publisher-name>Baishideng Publishing Group Inc</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">29930465</article-id>
      <article-id pub-id-type="pmc">6010941</article-id>
      <article-id pub-id-type="other">jWJG.v24.i23.pg2427</article-id>
      <article-id pub-id-type="doi">10.3748/wjg.v24.i23.2427</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Taking advantage of the potential of mesenchymal stromal cells in liver regeneration: Cells and extracellular vesicles as therapeutic strategies</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Fiore</surname>
            <given-names>Esteban Juan</given-names>
          </name>
          <aff>Laboratory of Gene Therapy, Instituto de Investigaciones en Medicina Traslacional, CONICET-Universidad Austral, Buenos Aires 999071, Argentina</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dom&#xED;nguez</surname>
            <given-names>Luciana Mar&#xED;a</given-names>
          </name>
          <aff>Laboratory of Gene Therapy, Instituto de Investigaciones en Medicina Traslacional, CONICET-Universidad Austral, Buenos Aires 999071, Argentina</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bayo</surname>
            <given-names>Juan</given-names>
          </name>
          <aff>Laboratory of Gene Therapy, Instituto de Investigaciones en Medicina Traslacional, CONICET-Universidad Austral, Buenos Aires 999071, Argentina</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Garc&#xED;a</surname>
            <given-names>Mariana Gabriela</given-names>
          </name>
          <aff>Laboratory of Gene Therapy, Instituto de Investigaciones en Medicina Traslacional, CONICET-Universidad Austral, Buenos Aires 999071, Argentina</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mazzolini</surname>
            <given-names>Guillermo Daniel</given-names>
          </name>
          <aff>Laboratory of Gene Therapy, Instituto de Investigaciones en Medicina Traslacional, CONICET-Universidad Austral, Buenos Aires 999071, Argentina. <email>gmazzoli@austral.edu.ar</email></aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn>
          <p>Author contributions: Fiore EJ collected the information, wrote manuscript and drawn the figures; Dom&#xED;nguez LM collected information and assembly the tables; Bayo J and Garc&#xED;a MG wrote and reviewed the manuscript critically; Mazzolini GD wrote, reviewed critically and final approval of manuscript; all authors approved the final version of the manuscript.</p>
          <p>Correspondence to: Guillermo Daniel Mazzolini, MD, PhD, Professor, Laboratory of Gene Therapy, Instituto de Investigaciones en Medicina Traslacional, CONICET-Universidad Austral, Av. Pte. Per&#xF3;n 1500 (B1629AHJ) Derqui-Pilar, Buenos Aires 999071, Argentina. <email>gmazzoli@austral.edu.ar</email></p>
          <p>Telephone: +54-230-4482618 Fax: +54-230-4482618</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>21</day>
        <month>6</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>21</day>
        <month>6</month>
        <year>2018</year>
      </pub-date>
      <volume>24</volume>
      <issue>23</issue>
      <fpage>2427</fpage>
      <lpage>2440</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>4</month>
          <year>2018</year>
        </date>
        <date date-type="rev-recd">
          <day>8</day>
          <month>5</month>
          <year>2018</year>
        </date>
        <date date-type="accepted">
          <day>2</day>
          <month>6</month>
          <year>2018</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement>
        <copyright-year>2018</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Cell-based therapies for acute and chronic liver diseases are under continuous progress. Mesenchymal stem/stromal cells (MSCs) are multipotent cells able to migrate selectively to damaged tissue and contribute to its healing and regeneration. The MSC pro-regenerative effect occurs due to their immunomodulatory capacity and their ability to produce factors that promote cell protection and survival. Likewise, it has been observed that part of their paracrine effect is mediated by MSC-derived extracellular vesicles (EVs). EVs contain proteins, lipids and nucleic acids (DNA, mRNA, miRNA, lncRNA) from the cell of origin, allowing for intercellular communication. Recently, different studies have demonstrated that MSC-derived EVs could reproduce, at least in part, the biological effects obtained by MSC-based therapies. Moreover, due to EVs&#x2019; stability for long periods of time and easy isolation methods they have become a therapeutic option to MSCs treatments. This review summarizes the latest results achieved in clinical trials using MSCs as cell therapy for liver regeneration, the role of EVs in liver physiopathology and the potential of MSCderived EVs as intercellular mediators and therapeutic tools in liver diseases.</p>
      </abstract>
      <kwd-group>
        <kwd>Mesenchymal stem cells</kwd>
        <kwd>Extracellular vesicles</kwd>
        <kwd>Cirrhosis</kwd>
        <kwd>Liver</kwd>
        <kwd>Acute damage</kwd>
        <kwd>Regeneration</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p><bold>Core tip:</bold> Cell-based therapies for acute and chronic liver diseases are very attractive strategies. In particular, mesenchymal stem/stromal cells (MSCs) are multipotent cells able to induce protective and pro-regenerative effects in different liver diseases. The mechanism through which MSCs support tissue regeneration is <italic>via</italic> secretion of paracrine factors, and solid evidence supports that part of these effects is mediated by extracellular vesicles (EVs). Therefore, EVs have become an attractive option in the research for new treatments in liver diseases.</p>
    <sec>
      <title>INTRODUCTION</title>
      <p>A diverse set of toxic, metabolic, and inflammatory insults result in liver diseases and imply different degrees of inflammation, apoptosis, and necrosis of parenchymal cells[<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B4" ref-type="bibr">4</xref>]. For example, acute liver failure (ALF) is characterized by a massive and sudden death of hepatocytes that lead to abrupt hepatocellular and systemic dysfunction[<xref rid="B3" ref-type="bibr">3</xref>]. Similarly, in patients with chronic liver disease an important loss of viable parenchymal cells is observed[<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B4" ref-type="bibr">4</xref>]. Cirrhosis is caused by diverse chronic liver diseases, such as viral hepatitis and chronic alcoholism[<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>]. Moreover, increases in the prevalence of hypertriglyceridemia, obesity and diabetes in developed countries have resulted in an increase in the incidence of non-alcoholic fatty liver disease (NAFLD)[<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>]. This condition is characterized by a lipid accumulation in the liver that could lead to hepatocytes apoptosis and inflammation. Regardless the liver chronic disease origin, the apoptosis of hepatocytes results in extracellular matrix accumulation that will affect the liver histoarchitecture of liver and ultimately impair its function[<xref rid="B4" ref-type="bibr">4</xref>]. It is well known that mesenchymal stem/stromal cells (MSCs) migrate toward injured organs where they can provide tissue protection and promote liver regeneration[<xref rid="B6" ref-type="bibr">6</xref>-<xref rid="B8" ref-type="bibr">8</xref>]. These properties make MSCs interesting tools to carry therapeutic genes in modern cellular-based therapeutic strategies[<xref rid="B6" ref-type="bibr">6</xref>]. It is accepted that the main mechanism through which MSCs support tissue regeneration is <italic>via</italic> secretion of paracrine factors[<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B9" ref-type="bibr">9</xref>]. However, solid evidence supports that part of these effects are mediated by extracellular vesicles (EVs)[<xref rid="B10" ref-type="bibr">10</xref>]. In this review, we first provide an update on clinical trials using MSCs in different liver diseases; second, the mechanisms involved in the therapeutic effects of MSCs; third, general EVs characteristics and their role in liver diseases, and finally, the role of MSC-derived EVs as therapeutic tools for liver regeneration.</p>
    </sec>
    <sec>
      <title>CLINICAL TRIALS INVOLVING THE USE OF MSCS IN LIVER DISEASES</title>
      <p>Clinical investigations using MSCs to treat a broad spectrum of degenerative diseases, including liver diseases, are increasing steadily in recent years[<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>]. The first clinical trial using MSCs was started in 2005 and 52 trials are registered up to now (CinicalTrial.gov and reviewed by Tsuchiya 2017[<xref rid="B13" ref-type="bibr">13</xref>]). MSCs are obtained from bone marrow in most of the studies, but other sources such as umbilical cord, adipose tissue and menstrual blood has also been tested (Figure <xref ref-type="fig" rid="F1">1A</xref>). It should be noted that, allogeneic transplantation is more commonly used than autologous (Figure <xref ref-type="fig" rid="F1">1B</xref>). Between liver diseases, most of the trials are destined to the treatment of liver cirrhosis (Figure <xref ref-type="fig" rid="F1">1C</xref>) and only 2 of them are in phase II/III (CinicalTrial.gov). Unfortunately, only 22 of 52 registered clinical trials have published their results (Table <xref ref-type="table" rid="T1">1</xref>). It is important to mention that MSCs were administered after culture <italic>in vitro</italic> between passages 3 to 6. Regarding the administration route, MSC transplant was performed by peripheral vein[<xref rid="B14" ref-type="bibr">14</xref>-<xref rid="B28" ref-type="bibr">28</xref>], hepatic artery[<xref rid="B29" ref-type="bibr">29</xref>-<xref rid="B33" ref-type="bibr">33</xref>], portal vein[<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B27" ref-type="bibr">27</xref>] or directly into the spleen[<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B34" ref-type="bibr">34</xref>,<xref rid="B35" ref-type="bibr">35</xref>]. One study performed on 12 patients showed similar therapeutic effects when MSCs were injected into the spleen or intravenously[<xref rid="B17" ref-type="bibr">17</xref>].</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Mesenchymal stem/stromal cells clinical trials for liver diseases</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead align="center">
            <tr>
              <td rowspan="2" align="left" colspan="1"><bold>Ref</bold>.</td>
              <td rowspan="2" colspan="1">
                <bold>Etiology or disease</bold>
              </td>
              <td rowspan="2" colspan="1">
                <bold>Cell source/origen</bold>
              </td>
              <td rowspan="2" colspan="1">
                <bold>Study design (<italic>n</italic>; groups)</bold>
              </td>
              <td colspan="3" rowspan="1">
                <bold>Cell administration condition</bold>
                <hr/>
              </td>
              <td rowspan="2" colspan="1">
                <bold>Phase</bold>
              </td>
              <td rowspan="2" colspan="1">
                <bold>Results</bold>
              </td>
              <td rowspan="2" colspan="1">
                <bold>Follow up</bold>
              </td>
              <td rowspan="2" colspan="1">
                <bold>Side effects</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <bold>Dose</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold><italic>P</italic> value</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>Route</bold>
              </td>
            </tr>
          </thead>
          <tbody align="center">
            <tr>
              <td align="left" rowspan="1" colspan="1">Mohamadnejad et al[<xref rid="B14" ref-type="bibr">14</xref>] 2007</td>
              <td rowspan="1" colspan="1">Cirrhosis</td>
              <td rowspan="1" colspan="1">BM/Auto</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 4</td>
              <td rowspan="1" colspan="1">1, 0.6 &#xD7; 10<sup>7</sup></td>
              <td rowspan="1" colspan="1">2-4</td>
              <td rowspan="1" colspan="1">IV</td>
              <td rowspan="1" colspan="1">I</td>
              <td rowspan="1" colspan="1">MELD &#x2193;</td>
              <td rowspan="1" colspan="1">12 mo</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Kharaziha et al[<xref rid="B15" ref-type="bibr">15</xref>] 2009</td>
              <td rowspan="1" colspan="1">Cirrhosis</td>
              <td rowspan="1" colspan="1">BM/Auto</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 8; 4 HBV 1 HCV 1 Alcohol 2 Control</td>
              <td rowspan="1" colspan="1">3.5 &#xD7; 10<sup>7</sup></td>
              <td rowspan="1" colspan="1">3-4</td>
              <td rowspan="1" colspan="1">PV/IV</td>
              <td rowspan="1" colspan="1">I/II</td>
              <td rowspan="1" colspan="1">MELD &#x2193;</td>
              <td rowspan="1" colspan="1">24 wk</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">El-Ansary et al[<xref rid="B16" ref-type="bibr">16</xref>] 2010</td>
              <td rowspan="1" colspan="1">Cirrhosis</td>
              <td rowspan="1" colspan="1">BM/Auto</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 12</td>
              <td rowspan="1" colspan="1">10 &#xD7; 10<sup>6</sup></td>
              <td rowspan="1" colspan="1">1</td>
              <td rowspan="1" colspan="1">IS/IV</td>
              <td rowspan="1" colspan="1">I</td>
              <td rowspan="1" colspan="1">MELD &#x2193;; no differences between IS <italic>vs</italic> IV</td>
              <td rowspan="1" colspan="1">6 mo</td>
              <td rowspan="1" colspan="1">NA</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Peng et al[<xref rid="B29" ref-type="bibr">29</xref>] 2011</td>
              <td rowspan="1" colspan="1">Cirrhosis (HBV)</td>
              <td rowspan="1" colspan="1">BM/Auto</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 158; 53 MSC 105 Control</td>
              <td rowspan="1" colspan="1">3.4-3.8 &#xD7; 10<sup>8</sup></td>
              <td rowspan="1" colspan="1">3</td>
              <td rowspan="1" colspan="1">HA</td>
              <td rowspan="1" colspan="1">I/II</td>
              <td rowspan="1" colspan="1">ALB &#x2191;, MELD &#x2193;</td>
              <td rowspan="1" colspan="1">48 mo</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Amer et al[<xref rid="B34" ref-type="bibr">34</xref>] 2011</td>
              <td rowspan="1" colspan="1">Cirrhosis (HCV)</td>
              <td rowspan="1" colspan="1">BM/Auto</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 40; 20 MSC 20 Control</td>
              <td rowspan="1" colspan="1">2 &#xD7; 10<sup>7</sup></td>
              <td rowspan="1" colspan="1">NA</td>
              <td rowspan="1" colspan="1">IS/IH</td>
              <td rowspan="1" colspan="1">I/II</td>
              <td rowspan="1" colspan="1">ALB &#x2191;, C.P &#x2193;, MELD &#x2193;</td>
              <td rowspan="1" colspan="1">6 mo</td>
              <td rowspan="1" colspan="1">Fever (50%), transient shivering (15%)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">El-Ansary et al[<xref rid="B17" ref-type="bibr">17</xref>] 2012</td>
              <td rowspan="1" colspan="1">Cirrhosis (HCV)</td>
              <td rowspan="1" colspan="1">BM/Auto</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 25; 9 MSC 6 Hep. Diff. 10 Control</td>
              <td rowspan="1" colspan="1">1 &#xD7; 10<sup>6</sup>/kg MSC or 40% HLCs and 60% MSCs</td>
              <td rowspan="1" colspan="1">5</td>
              <td rowspan="1" colspan="1">IV</td>
              <td rowspan="1" colspan="1">II</td>
              <td rowspan="1" colspan="1">ALB&#x2191;, MELD &#x2193;, no differences between HLCs <italic>vs</italic> MSCs.</td>
              <td rowspan="1" colspan="1">6 mo</td>
              <td rowspan="1" colspan="1">NA</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Zhang et al[<xref rid="B18" ref-type="bibr">18</xref>] 2012</td>
              <td rowspan="1" colspan="1">Cirrhosis (HBV)</td>
              <td rowspan="1" colspan="1">UC/Allo</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 45; 30 MSC 15 Control</td>
              <td rowspan="1" colspan="1">0.5 &#xD7; 10<sup>6</sup>/kg every 4 wk, 3 times</td>
              <td rowspan="1" colspan="1">3-4</td>
              <td rowspan="1" colspan="1">IV</td>
              <td rowspan="1" colspan="1">I/II</td>
              <td rowspan="1" colspan="1">ALB &#x2191;, MELD&#x2193;, ascites &#x2193;</td>
              <td rowspan="1" colspan="1">48 wk</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Shi et al[<xref rid="B19" ref-type="bibr">19</xref>] 2012</td>
              <td rowspan="1" colspan="1">Acute-on-chronic Liver failure (HBV cirrhosis)</td>
              <td rowspan="1" colspan="1">UC/Allo</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 43; 34 MSC 9 Control</td>
              <td rowspan="1" colspan="1">0.5 &#xD7; 10<sup>6</sup>/kg every 4 wk, 3 times</td>
              <td rowspan="1" colspan="1">3-4</td>
              <td rowspan="1" colspan="1">IV</td>
              <td rowspan="1" colspan="1">I/II</td>
              <td rowspan="1" colspan="1">ALB &#x2191;, PT &#x2191;, MELD &#x2193;, SR&#x2191;</td>
              <td rowspan="1" colspan="1">72 wk</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Mohamadnejad et al[<xref rid="B20" ref-type="bibr">20</xref>] 2013</td>
              <td rowspan="1" colspan="1">Cirrhosis</td>
              <td rowspan="1" colspan="1">BM/Auto</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 25; 14 MSC 11 Control</td>
              <td rowspan="1" colspan="1">2 &#xD7; 10<sup>8</sup></td>
              <td rowspan="1" colspan="1">3-4</td>
              <td rowspan="1" colspan="1">IV</td>
              <td rowspan="1" colspan="1">II</td>
              <td rowspan="1" colspan="1">No beneficial effect</td>
              <td rowspan="1" colspan="1">12 mo</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Wang et al[<xref rid="B21" ref-type="bibr">21</xref>] 2013</td>
              <td rowspan="1" colspan="1">UDCA-resistant PBC</td>
              <td rowspan="1" colspan="1">UC/Allo</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 7</td>
              <td rowspan="1" colspan="1">0.5 &#xD7; 10<sup>6</sup>/kg every 4 wk, 3 times</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">IV</td>
              <td rowspan="1" colspan="1">I/II</td>
              <td rowspan="1" colspan="1">ALP&#x2193;, &#x3B3;-GT &#x2193;, quality of life&#x2191; (fatigue&#x2193;, pruritus&#x2193;)</td>
              <td rowspan="1" colspan="1">48 wk</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Amin et al[<xref rid="B35" ref-type="bibr">35</xref>] 2013</td>
              <td rowspan="1" colspan="1">Cirrhosis</td>
              <td rowspan="1" colspan="1">BM/Auto</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 20</td>
              <td rowspan="1" colspan="1">10 &#xD7; 10<sup>6</sup></td>
              <td rowspan="1" colspan="1">2</td>
              <td rowspan="1" colspan="1">IS</td>
              <td rowspan="1" colspan="1">I/II</td>
              <td rowspan="1" colspan="1">ALT &#x2193;,AST &#x2193;,BIL &#x2193;, PT &#x2193;, ALB&#x2191;, PT&#x2191;</td>
              <td rowspan="1" colspan="1">24 wk</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Jang et al[<xref rid="B30" ref-type="bibr">30</xref>] 2014</td>
              <td rowspan="1" colspan="1">Cirrhosis</td>
              <td rowspan="1" colspan="1">BM/Auto</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 11</td>
              <td rowspan="1" colspan="1">5 &#xD7; 10<sup>7</sup> every 4 wk, 2 times</td>
              <td rowspan="1" colspan="1">4-5</td>
              <td rowspan="1" colspan="1">HA</td>
              <td rowspan="1" colspan="1">II</td>
              <td rowspan="1" colspan="1">C.P &#x2193;, TGF-&#x3B2; &#x2193;, &#x3B1;SMA &#x2193;, collagen1 &#x2193;, fibrosis &#x2193;,</td>
              <td rowspan="1" colspan="1">20 wk</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Wang et al[<xref rid="B18" ref-type="bibr">18</xref>] 2014</td>
              <td rowspan="1" colspan="1">UDCA-resistant PBC</td>
              <td rowspan="1" colspan="1">BM/Allo</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 10</td>
              <td rowspan="1" colspan="1">3-5 &#xD7; 10<sup>5</sup>/kg</td>
              <td rowspan="1" colspan="1">3-5</td>
              <td rowspan="1" colspan="1">IV</td>
              <td rowspan="1" colspan="1">I/II</td>
              <td rowspan="1" colspan="1">ALT &#x2193;, AST &#x2193;, &#x3B3;GT, BIL &#x2193;, IgM &#x2193;, Tregs &#x2191;, IL-10&#x2191;, CD8+T cells&#x2193;</td>
              <td rowspan="1" colspan="1">12 mo</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Salama et al[<xref rid="B23" ref-type="bibr">23</xref>] 2014</td>
              <td rowspan="1" colspan="1">Cirrhosis</td>
              <td rowspan="1" colspan="1">BM/Auto</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 40; 20 MSC 20 Control</td>
              <td rowspan="1" colspan="1">1 &#xD7; 10<sup>6</sup>/kg</td>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">IV</td>
              <td rowspan="1" colspan="1">II</td>
              <td rowspan="1" colspan="1">ALT&#x2193;, AST&#x2193;,BIL&#x2193;, ALB&#x2191;, PT&#x2191;, C.P&#x2193;, ascites &#x2193;</td>
              <td rowspan="1" colspan="1">26 wk</td>
              <td rowspan="1" colspan="1">NA</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Xu et al[<xref rid="B31" ref-type="bibr">31</xref>] 2014</td>
              <td rowspan="1" colspan="1">Cirrhosis</td>
              <td rowspan="1" colspan="1">BM/Auto</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 56; 27 MSC 29 Control</td>
              <td rowspan="1" colspan="1">0.75 &#xD7; 10<sup>6</sup>/kg</td>
              <td rowspan="1" colspan="1">NA</td>
              <td rowspan="1" colspan="1">HA</td>
              <td rowspan="1" colspan="1">II/III</td>
              <td rowspan="1" colspan="1">ALB&#x2191;, MELD&#x2193;, &#x2191; Tregs/Th17 cell ratio, IL-17&#x2193;, TNF&#x3B1;&#x2193;, IL-6&#x2193;, TGF-&#x3B2; &#x2191;</td>
              <td rowspan="1" colspan="1">24 wk</td>
              <td rowspan="1" colspan="1">NA</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Suk et al[<xref rid="B32" ref-type="bibr">32</xref>] 2016</td>
              <td rowspan="1" colspan="1">Cirrhosis</td>
              <td rowspan="1" colspan="1">BM/Auto</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 55; 18 MSC (&#xD7; 1 d) 19 MSC (&#xD7; 2 d) 18 Control</td>
              <td rowspan="1" colspan="1">5 &#xD7; 10<sup>7</sup> (1 mo post BM asp.) /5 &#xD7; 10<sup>7</sup> (1 and 2 m post BM asp.)</td>
              <td rowspan="1" colspan="1">4-5</td>
              <td rowspan="1" colspan="1">HA</td>
              <td rowspan="1" colspan="1">II</td>
              <td rowspan="1" colspan="1">C.P &#x2193;, fibrosis &#x2193;</td>
              <td rowspan="1" colspan="1">12 mo</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Zhang et al[<xref rid="B24" ref-type="bibr">24</xref>] 2017</td>
              <td rowspan="1" colspan="1">Ischemic-type biliary lesions</td>
              <td rowspan="1" colspan="1">UC/Allo</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 82; 12 MSC 70 Control</td>
              <td rowspan="1" colspan="1">1 &#xD7; 10<sup>6</sup>/kg; week 1, 2, 4, 8, 12 and 16</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">IV</td>
              <td rowspan="1" colspan="1">II/III</td>
              <td rowspan="1" colspan="1">BIL&#x2193;,ALP&#x2193;, &#x3B3;GT &#x2193;, graft survival &#x2191;</td>
              <td rowspan="1" colspan="1">24 mo</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Detry et al[<xref rid="B25" ref-type="bibr">25</xref>] 2017</td>
              <td rowspan="1" colspan="1">Liver transplantation</td>
              <td rowspan="1" colspan="1">BM/Allo</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 20; 10 MSC 10 Control</td>
              <td rowspan="1" colspan="1">1.5-3 &#xD7; 10<sup>6</sup>/kg; day 3 post-transplant</td>
              <td rowspan="1" colspan="1">2-3</td>
              <td rowspan="1" colspan="1">IV</td>
              <td rowspan="1" colspan="1">I/II</td>
              <td rowspan="1" colspan="1">No beneficial effect</td>
              <td rowspan="1" colspan="1">6 mo</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Sakai et al[<xref rid="B33" ref-type="bibr">33</xref>] 2017</td>
              <td rowspan="1" colspan="1">Cirrhosis</td>
              <td rowspan="1" colspan="1">AT/Auto</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 4</td>
              <td rowspan="1" colspan="1">6.6 &#xD7; 10<sup>5</sup>/kg</td>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">HA</td>
              <td rowspan="1" colspan="1">I</td>
              <td rowspan="1" colspan="1">ALB &#x2191;, PT&#x2193;</td>
              <td rowspan="1" colspan="1">1 mo</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Shi et al[<xref rid="B26" ref-type="bibr">26</xref>] 2017</td>
              <td rowspan="1" colspan="1">Liver transplantation</td>
              <td rowspan="1" colspan="1">UC/Allo</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 20; 14 MSC 13 Control</td>
              <td rowspan="1" colspan="1">1 &#xD7; 10<sup>6</sup>/kg; every 4 wk, 3 times</td>
              <td rowspan="1" colspan="1">3-4</td>
              <td rowspan="1" colspan="1">IV</td>
              <td rowspan="1" colspan="1">I</td>
              <td rowspan="1" colspan="1">ALT&#x2193;, AST&#x2193;, BIL &#x2193;, improve liver allograft histology, acute rejection&#x2193; (&#x2191; peripheral Tregs, &#x2191; Tregs/Th17 cell ratio).</td>
              <td rowspan="1" colspan="1">12 wk</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Hartleif et al[<xref rid="B27" ref-type="bibr">27</xref>] 2017</td>
              <td rowspan="1" colspan="1">Pediatric liver transplantation</td>
              <td rowspan="1" colspan="1">BM/Allo</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 7</td>
              <td rowspan="1" colspan="1">1 &#xD7; 10<sup>6</sup>/kg; day 0 and day 2 post-transplantation</td>
              <td rowspan="1" colspan="1">2-3</td>
              <td rowspan="1" colspan="1">PV/IV</td>
              <td rowspan="1" colspan="1">I</td>
              <td rowspan="1" colspan="1">NA</td>
              <td rowspan="1" colspan="1">24 mo</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Lin et al[<xref rid="B28" ref-type="bibr">28</xref>] 2017</td>
              <td rowspan="1" colspan="1">Acute-on-chronic Cirrhosis (HBV)</td>
              <td rowspan="1" colspan="1">BM/Allo</td>
              <td rowspan="1" colspan="1"><italic>n</italic> = 110; 56 MSC 54 Control</td>
              <td rowspan="1" colspan="1">1-10 &#xD7; 10<sup>5</sup> cells/kg; 1/wk, 4 wk</td>
              <td rowspan="1" colspan="1">5-6</td>
              <td rowspan="1" colspan="1">IV</td>
              <td rowspan="1" colspan="1">I/II</td>
              <td rowspan="1" colspan="1">MELD&#x2193;, SR&#x2191;, infections&#x2193;</td>
              <td rowspan="1" colspan="1">24 wk</td>
              <td rowspan="1" colspan="1">None</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>P: Passage; BM: Bone Marrow; Allo: Allogeneic; Auto: Autologous; IV: Intravenous Infusion; MELD: Model for end-stage Liver Disease; HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; IS: Intrasplenic; IH: Intrahepatic; NA: Not available; HA: Hepatic artery; CP: Child-Pugh score; HLC: Hepatocyte-like cells; UC: Umbilical cord; SR: Survival rate; Cr: Creatinine; BIL: Bilirubin; PBC: Primary biliary cirrhosis; UDCA: Ursodeoxycholic acid; Hep. Diff.: Hepatocyte differentiated; PT: Prothrombin time; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; &#x3B3;-GT: &#x3B3;-glutamyltranspeptidase; Asp: Aspiration.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Mesenchymal stem/stromal cells clinical trials in liver disease. A: MSCs clinical trials classified by cell source; B: MSCs clinical trials classified by transplant type; C: MSCs clinical trials classified by liver disease treated. Data from <uri xlink:type="simple" xlink:href="http//www.clinicaltrial.gov">http//www.clinicaltrial.gov</uri>. <italic>n</italic>: Number of clinical trials; MSCs: Mesenchymal stem/stromal cells; BM: Bone marrow; UC: Umbilical cord; AT: Adipose tissue.</p>
        </caption>
        <graphic xlink:href="WJG-24-2427-g001"/>
      </fig>
      <p>In general, MSC administration in patients with different liver pathologies proved to be feasible and safe (Table <xref ref-type="table" rid="T1">1</xref>). Regarding their efficacy, studies demonstrated that MSCs exert positive effects on liver function by increase in serum levels of albumin and improving coagulation or decreasing bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and &#x3B3;-glutamyltransferase (&#x3B3;-GT)[<xref rid="B17" ref-type="bibr">17</xref>-<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B21" ref-type="bibr">21</xref>-<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B33" ref-type="bibr">33</xref>-<xref rid="B35" ref-type="bibr">35</xref>]. In addition, the MELD (Model for End-stage Liver Disease) and Child-Pugh scores were improved after MSC treatment[<xref rid="B14" ref-type="bibr">14</xref>-<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B28" ref-type="bibr">28</xref>-<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B34" ref-type="bibr">34</xref>] (Table <xref ref-type="table" rid="T1">1</xref>). Furthermore, in some studies it was demonstrated that the application of MSCs not only improved patient&#x2019;s quality of life but also modulated the immune response of patients[<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B31" ref-type="bibr">31</xref>]. In this sense, a randomized clinical trial using autologous BM-derived MSCs in patients with hepatitis B virus-related liver cirrhosis resulted in an improvement of liver function, an increase in Treg cells, and a decrease in Th17 cells, serum levels of interleukin (IL)-17, tumor necrosis factor alpha (TNF-&#x3B1;) and IL-6; in addition, tumor growth factor beta (TGF-&#x3B2;) levels were increased in comparison with control group[<xref rid="B31" ref-type="bibr">31</xref>]. Similar results were reported in a phase I/II clinical trial in patients with primary biliary cirrhosis (PBC) transplanted with allogeneic MSCs that showed a reduction in the number of CD8+ T-cells and an increment of Treg cells and IL-10 serum levels[<xref rid="B22" ref-type="bibr">22</xref>].</p>
      <p>Recently, Suk et al[<xref rid="B32" ref-type="bibr">32</xref>] reported a phase II clinical trial comparing the effects of one or two doses of autologous BM-derived MSC therapy with a control group in alcoholic patients. The authors observed that liver fibrosis quantification diminished after cell treatment, although no significant differences in fibrosis area were found between one and two doses. Importantly, no evidence of tumor formation was found during the follow-up in the MSC-treated groups[<xref rid="B32" ref-type="bibr">32</xref>].</p>
      <p>On the other hand, MSCs were used to diminish hepatocellular damage in acute liver diseases. Recently, a phase II clinical trial in acute-on-chronic liver failure compared the standard medical treatment with one dose of allogeneic BM-derived MSC therapy[<xref rid="B28" ref-type="bibr">28</xref>]. In this study, MSC treatment demonstrated to be safe and able to improve bilirubin levels and MELD score. Interestingly, MSC transplant increased survival rate and decreased severe infection events[<xref rid="B28" ref-type="bibr">28</xref>].</p>
      <p>Long-term immunosuppression is frequently associated with impairment in patients&#xB4; quality of life and increased risk of infection or cancer. Therefore, considering their immunomodulatory capacity, MSCs can be used to induce tolerance after liver transplantation. In this regard, Detry et al[<xref rid="B25" ref-type="bibr">25</xref>] reported that MSC infusion 3 d after liver transplant was feasible, safe and well tolerated. No opportunistic infections or <italic>de novo</italic> cancer were detected in 12 mo follow-up. However, no difference was observed in peripheral blood CD4<sup>+</sup> T cell proportion and immunosuppression could not be withdrawn in MSC-treated patients. In addition, the administration of umbilical cord-derived MSCs as therapy to prolong graft-survival in patients with severe ischemic-type biliary lesions after liver transplantation was also evaluated[<xref rid="B24" ref-type="bibr">24</xref>]. Six doses of MSCs were infused intravenously every 2-4 wk, and patients were followed-up for 2 years and compared with a prospective cohort of patients treated with standard therapy. Remarkably, MSCs were safe, improved hepatic function, prolonged graft-survival and did not induce cancer or increase microbial infection events[<xref rid="B24" ref-type="bibr">24</xref>]. In conclusion, these results demonstrated that MSC therapy is a safe procedure, especially in the field of solid organ transplant where intense and prolonged immunosuppression is required. Moreover, MSC administration could prevent the development of opportunistic infections or <italic>de novo</italic> tumor formation. All considered, the promising information generated in the clinic opens the possibility for further studies to determine the optimal protocol conditions of MSC application needed to induce tolerance after liver transplant.</p>
      <p>Application of MSCs for treatment of either acute or chronic liver diseases has a promising future in the clinic. In acute liver diseases, MSCs could have a role decreasing liver damage progression or as a bridge for liver transplant. In chronic liver diseases, MSCs could contribute to decrease liver damage, to ameliorate the degree of fibrosis, and even to avoid the need for transplant in some particular cases. On the other hand, in the post-transplant setting, MSC therapy could extend the graft survival and/or decrease the amount of immunosuppression. However, it is extremely important to understand that therapeutic potential of MSCs is an open question, and the information regarding source of MSCs, culture conditions, pre-condition protocols before cell transplantation, administration route, number of doses, and time of treatment are very heterogeneous and standardization is needed.</p>
    </sec>
    <sec>
      <title>MECHANISM OF ACTION OF MSCS IN LIVER REGENERATION</title>
      <p>As detailed above, is necessary to understand the mechanisms that mediate MSCs therapeutic effects prior to continuing with its clinical application. The understanding of MSC biology has grown considerably. In the last decade, many mechanisms involved in their regenerative potential have been identified. These mechanisms involve, at least in part, migration toward injured tissues, immunomodulatory properties, differentiation and/or secretion of regenerative factors, which induce cell survival and proliferation[<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B37" ref-type="bibr">37</xref>]. It has been described that MSCs can be recruited to inflamed tissue by classic mechanism of blood stream migration: Rolling, adherence to endothelium and transmigration[<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B36" ref-type="bibr">36</xref>]. The injured liver produces signals that induce migration and homing of different cell types[<xref rid="B38" ref-type="bibr">38</xref>,<xref rid="B39" ref-type="bibr">39</xref>]. Both, chronic and acute liver injury induce apoptosis and necrosis of hepatocytes and/or cholangiocytes, infiltration of leucocytes, monocytes and activation of Kupffer cells (KCs), liver sinusoidal endothelial cells (LSECs) and hepatic stellate cells (HeSCs)[<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B40" ref-type="bibr">40</xref>]. In this context, MSCs could be attracted by several chemokines, cytokines and factors secreted by the damaged liver microenvironment, such as IL-1&#x3B2;, IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1), growth-regulated protein (GRO), TNF-&#x3B1;, TGF-&#x3B2;1, platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and stromal cell-derived factor 1 (SDF-1) among others. Receptors for these chemoattractants were found to be expressed in MSCs allowing them to migrate to the injured liver[<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B36" ref-type="bibr">36</xref>].</p>
      <p>The differentiation potential of MSCs has been considered one of the advantages for their regenerative application[<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B41" ref-type="bibr">41</xref>-<xref rid="B43" ref-type="bibr">43</xref>]. By definition, MSCs give rise to cells of mesodermal lineages including osteoblasts, adipoblasts and chondroblasts[<xref rid="B44" ref-type="bibr">44</xref>]. Furthermore, there are many reports demonstrating that MSCs might differentiate to ectodermal (neurons), endodermal (hepatocytes) as well as other mesodermal lineages (cardiomyocytes), but this field remains very controversial[<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B41" ref-type="bibr">41</xref>]. In this context, a putative mechanism postulated for liver regeneration was the MSC differentiation into hepatocyte-like cells[<xref rid="B45" ref-type="bibr">45</xref>]. A number of differentiation <italic>in vitro</italic> protocols were explored in MSCs obtained from bone marrow, adipose tissue or umbilical cord demonstrating that MSC-derived cells acquired characteristic markers and functions of immature and mature hepatocytes (reviewed in Fiore et al[<xref rid="B7" ref-type="bibr">7</xref>]). In fact, a clinical trial compared the effect of autologous BM-MSCs undifferentiated or differentiated into hepatocyte-like cells in patients with cirrhosis. Despite the improvement of liver function, there was no significant difference between undifferentiated or differentiated MSC-based treatment[<xref rid="B17" ref-type="bibr">17</xref>]. However, difficulties to study and reproduce the <italic>in vitro</italic> differentiation and <italic>in vivo</italic> tracking after their administration, makes the MSC differentiation to hepatocytes a controversial field. This difficulty is due, at least in part, to unspecificity and/or unreliability of methods/trackers/reagents frequently used for the identification of cells or the phenotype they might acquire after their transplantation[<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B47" ref-type="bibr">47</xref>]. It should be noted that track able MSCs by GFP expression is detectable in the liver up to 7 d after transplant and then the signal rapidly decreases in animal models[<xref rid="B48" ref-type="bibr">48</xref>]. Moreover, some evidence indicated that in spite of the MSC homing to the liver, the rate of differentiation to hepatocyte-like cells is very low (less to 1%)[<xref rid="B49" ref-type="bibr">49</xref>,<xref rid="B50" ref-type="bibr">50</xref>]. Together, this information demonstrates that the main regenerative effect of MSCs cannot be explained by the differentiation to hepatocyte-like cells.</p>
      <p>Broad scientific consensus states that the regenerative effect of MSCs is due to paracrine mechanisms. The versatility of MSCs makes them able to differentially express factors depending on the surrounding microenvironment[<xref rid="B51" ref-type="bibr">51</xref>]. In the context of liver fibrosis, it was observed that MSCs produce high levels of anti-apoptotic growth factors such as SDF-1, VEGF, hepatocyte growth factor (HGF) and insulin-like growth factor (IGF)-I[<xref rid="B9" ref-type="bibr">9</xref>]. Also, the release of HGF, fibroblast growth factor (FGF), IL-6, fibrinogen and TGF-&#x3B1; can induce hepatocyte proliferation[<xref rid="B51" ref-type="bibr">51</xref>]. In addition, HGF and epidermal growth factor (EGF) can induce hepatic progenitor cell proliferation and differentiation[<xref rid="B52" ref-type="bibr">52</xref>] and VEGF increases angiogenesis, an important event for liver regeneration[<xref rid="B53" ref-type="bibr">53</xref>]. Moreover, IL-10, HGF and IGF-I produced by MSCs can reduce fibrogenesis by inhibition of HeSCs activation and proliferation[<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B9" ref-type="bibr">9</xref>]. MSCs also secrete factors involved in extracellular matrix remodeling and chemokines that attract immune cells which could modulate their function[<xref rid="B51" ref-type="bibr">51</xref>]. In this way, <italic>in vivo</italic> administration of conditioned medium (CM) obtained from MSC cultures can be effective to reduce liver injury. It was reported that the administration of MSC-derived CM significantly improved short-term survival in a D-galactosamine-induced rat model of fulminant hepatic failure[<xref rid="B54" ref-type="bibr">54</xref>,<xref rid="B55" ref-type="bibr">55</xref>]. Furthermore, MSC-CM therapy had great inhibitory effects on hepatocellular death reducing hepatocyte apoptosis in a 90%. In addition, an increase in liver regeneration programs and number of proliferating hepatocytes was observed[<xref rid="B55" ref-type="bibr">55</xref>]. Subsequently, it was demonstrated that EVs, present in CM, are partly responsible of the therapeutic effects of MSCs[<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B56" ref-type="bibr">56</xref>].</p>
    </sec>
    <sec>
      <title>EXTRACELLULAR VESICLES</title>
      <p>Although, EVs were described as intracellular mediators many years ago, they have recently generated great interest as therapeutic and diagnostic tools. Initially, &#x201C;extracellular vesicle&#x201D; was used to refer to all kind of vesicles released by cells. Nevertheless, the increased knowledge of their biology allowed to distinguish between different types of vesicles[<xref rid="B57" ref-type="bibr">57</xref>]. Exosomes (50-100 nm in diameter) are homogenous and the largest family of EVs and are different from microvesicles (100-1000 nm) and apoptotic bodies (500-2000 nm) in size and biogenesis[<xref rid="B58" ref-type="bibr">58</xref>]. While exosomes are originated from multivesicular bodies (MVBs), microvesicles are originated directly from plasma membrane and released to extracellular space[<xref rid="B58" ref-type="bibr">58</xref>]. At present, vesicles can only be fractioned according to their sizes and no specific markers have been described. Due to a large heterogeneity in methods of isolation and terminology in the past published results, in this review we will refer to exosomes and microvesicles as &#x201C;EVs&#x201D;. In order to define a minimal criteria for EV characterization, the International Society for Extracellular Vesicles (ISEV) suggests a semi-quantitative analysis for typical protein marker, such as CD9, CD63, CD81, Alix or TSG101, size analysis and morphology examination[<xref rid="B59" ref-type="bibr">59</xref>]. In addition to these specific proteins, EVs contain a large number of proteins (growth factors, cytokines, vesicles proteins), DNAs, mRNAs, microRNAs (miRNAs), long non-coding RNAs (lncRNAs)[<xref rid="B57" ref-type="bibr">57</xref>,<xref rid="B59" ref-type="bibr">59</xref>]. An interesting characteristic of EVs is that they can be charged with specific components of the cell of origin, and this &#x201C;cargo&#x201D; could be modified by different stimuli and microenvironment conditions[<xref rid="B58" ref-type="bibr">58</xref>]. As mentioned above, it has been demonstrated that EVs are involved in the paracrine effects of MSCs, but as EVs are implicated in many intercellular communications, we will first describe their implication in liver diseases.</p>
    </sec>
    <sec>
      <title>EVS IN LIVER DISEASES</title>
      <p>EVs have been implicated in a number of physiological and pathophysiological processes, such as immune response, angiogenesis, tissue regeneration, tumorigenesis/metastasis and neurodegenerative diseases[<xref rid="B60" ref-type="bibr">60</xref>-<xref rid="B62" ref-type="bibr">62</xref>]. In patients with primary biliary cirrhosis it was demonstrated that serum exosomes are taken up by peripheral monocytes and dendritic cells, resulting in the up regulation of co-stimulatory molecules[<xref rid="B63" ref-type="bibr">63</xref>]. Interestingly, serum circulating EVs present different miRNA composition in cirrhotic patients when compared with healthy controls[<xref rid="B63" ref-type="bibr">63</xref>,<xref rid="B64" ref-type="bibr">64</xref>]. Recent findings demonstrated that EVs are implicated in viral hepatitis, drug-induced injury, alcohol injury, non-alcoholic steatohepatitis and biliary injury[<xref rid="B65" ref-type="bibr">65</xref>,<xref rid="B66" ref-type="bibr">66</xref>].</p>
      <sec>
        <title>EVs derived from parenchymal cells</title>
        <p>Exosomes transport a variety of macromolecules that could act as signals between donor and recipient cells. <italic>In vitro</italic> studies demonstrated that liver parenchymal cells produce EVs that are involved in many physiological and pathophysiological processes[<xref rid="B65" ref-type="bibr">65</xref>,<xref rid="B66" ref-type="bibr">66</xref>]. For instance, it was demonstrated that there is an increase in the number of circulating exosomes with proliferative effect on hepatocytes after ischemia/reperfusion injury[<xref rid="B67" ref-type="bibr">67</xref>]. Nojima et al[<xref rid="B67" ref-type="bibr">67</xref>] reported that EVs derived from hepatocytes, but no other liver cells can induce hepatocyte proliferation <italic>in vitro</italic>. It should be noted that hepatocyte-derived EVs exert their effect in a dose-dependent manner. Furthermore, their administration in mice under ischemia/reperfusion liver injury or after 70% hepatectomy promotes hepatocyte proliferation and liver regeneration. Similarly, Herrera et al[<xref rid="B68" ref-type="bibr">68</xref>] showed that hepatic progenitor cell-derived EVs promote hepatocyte proliferation, suppress cell death, and accelerate liver regeneration in rats after hepatectomy. The author suggested that this effect is mediated by the delivery of RNA by EVs to target cells. It is worth mention, that current data demonstrated that hepatocyte-derived exosome properties are mediated by fusion with target hepatocytes transferring their cargos[<xref rid="B67" ref-type="bibr">67</xref>,<xref rid="B69" ref-type="bibr">69</xref>,<xref rid="B70" ref-type="bibr">70</xref>]. For example, hepatocyte-derived EVs transfer neutral ceramidase and sphingosine kinase 2 (SK2) within hepatocytes resulting in the induction of sphingosine-1-phosphate (S1P), a demonstrated promoter of cell proliferation[<xref rid="B67" ref-type="bibr">67</xref>] (Figure <xref ref-type="fig" rid="F2">2</xref>). Further studies of the same group showed that CXCR1 is required for packaging of SK2 into exosomes and CXCR2 regulates neutral sphingomyelinase activity and there by neutral ceramidase production[<xref rid="B71" ref-type="bibr">71</xref>].</p>
        <fig id="F2" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Extracellular vesicles as paracrine mediator in liver disease and therapeutics potential of mesenchymal stem/stromal cells. After ischemia reperfusion injury (I/R) or hepatectomy, hepatocytes (1) HPCs (2) release EVs with the ability to induce hepatocyte proliferation. (3) HPC-derived EVs stimulate LSECs and macrophages production of proliferative cytokines such as IL25 and IL17B. (4) On the other hand, free fatty acids induce the production of hepatocyte-derived EVs that result in the activation of quiescent HeSCs and pro-inflammatory macrophages (M1). (5) During chronic hepatitis C virus infection, EVs secreted by HCV-infected hepatocytes induce activation of HeSCs. (6) EVs secreted by hepatocytes after alcohol injury (containing CD40L and miRNAs) induce activation of monocytes and HeSCs. It seems to be a balance between EVs derived from active or quiescent HeSCs that promotes or inhibits fibrogenesis. Activated HeSC-derived EVs induce activation of quiescent HeSCs trough CCN2 (7) and quiescent HeSCs inhibit activated HeSCs transferring Twist1 or miRNA199a-5p (8). LSEC-derived EVs could also regulate HeSC activation (9). MSC-EVs induce hepatocyte proliferation, reduce oxidative stress and apoptosis, and modulate inflammatory response by carrying GPX1 or SK2 (10). Engineered MSC-EVs transferring miRNA-122, miRNA 181 5p and miRNA-223 have potential effects. The effects of MSC-EVs on HeSCs, hepatic macrophages, LSEC and infiltrated cells populations remain poorly explored. Green arrows: Inactivation of HeSCs; Red arrows: Activation of HeSCs; Blue arrow: Proliferative effect; Colors spots represent EVs from different cell origin; NCDase: Neutral ceramidase; SK2: Sphingosine kinase 2; S1P: Sphingosine-1-phosphate; IL: Interleukin; SK1: Sphingosine kinase 1; CCN2: Connective tissue growth factor; Twist1: Basic helix-loop-helix transcription factor; GPX1: Glutathione peroxidase 1; HCV: Hepatitis C virus; EVs: Extracellular vesicles.</p>
          </caption>
          <graphic xlink:href="WJG-24-2427-g002"/>
        </fig>
        <p>On the other hand, hepatocyte-derived EVs in a nonalcoholic steatohepatitis (NASH) model interact with macrophages inducing an inflammatory phenotype[<xref rid="B72" ref-type="bibr">72</xref>] (Figure <xref ref-type="fig" rid="F2">2</xref>). Activation of the death receptor 5 (DR-5) expressed on hepatocytes by free fatty acid induces there lease of EVs that could stimulate IL1&#x3B2; and IL-6 expression on macrophages[<xref rid="B72" ref-type="bibr">72</xref>]. On the same line, EVs derived from palmitic acid (PA) stimulated hepatoma cells (Huh7 and HepG2) induce a profibrogenic phenotype on HeSCs[<xref rid="B73" ref-type="bibr">73</xref>]. Moreover, the activation of HeSCs seems to be related with the presence of miRNA-122 and miRNA-192 in the EVs[<xref rid="B73" ref-type="bibr">73</xref>] (Figure <xref ref-type="fig" rid="F2">2</xref>). Similarly, an increase in the number of circulating exosomes in mice is observed after chronic alcohol consumption[<xref rid="B74" ref-type="bibr">74</xref>]. Furthermore, <italic>in vitro</italic> incubation of hepatocytes with ethanol not only increases the release of exosomes but also allows monocyte activation through miRNA-122 horizontal transfer[<xref rid="B74" ref-type="bibr">74</xref>,<xref rid="B75" ref-type="bibr">75</xref>]. Remarkably, circulating EVs obtained from patients with alcoholic hepatitis show higher levels of miRNA-30a, miRNA-192 and, in particular, miRNA-122 than those obtained from heathy donors[<xref rid="B74" ref-type="bibr">74</xref>] (Figure <xref ref-type="fig" rid="F2">2</xref>).</p>
        <p>EVs have also been implicated in horizontal transfer of information in chronic hepatitis C infection between hepatocytes and HeSCs. Devhare et al[<xref rid="B76" ref-type="bibr">76</xref>] demonstrated that EVs derived from HCV-infected hepatocytes transfer viral RNAs that increases the expression of profibrogenic markers on HeSCs. Interestingly, these EVs carry miR-19a that activates the STAT3 signaling, enhancing the expression of TGF-&#x3B2; and IL-6. Importantly, miR-19a up-regulation was observed in HCV-infected hepatocytes and in sera of chronic HCV patients with fibrosis[<xref rid="B76" ref-type="bibr">76</xref>,<xref rid="B77" ref-type="bibr">77</xref>] (Figure <xref ref-type="fig" rid="F2">2</xref>). Moreover, Seo et al[<xref rid="B78" ref-type="bibr">78</xref>] demonstrated that EVs are implicated in HeSCs activation <italic>via</italic> toll-like receptor 3 with the subsequent activation of &#x3B3;&#x3B4; T cell population exacerbating liver fibrosis. Regarding other liver parenchymal cells, the role of cholangiocyte-derived EVs has been less studied. However, the presence of circulating EVs with altered miRNA composition and immunostimulatory functions on patients with PBC could suggest a role of cholangiocyte-derived EVs on this disease[<xref rid="B63" ref-type="bibr">63</xref>,<xref rid="B64" ref-type="bibr">64</xref>].</p>
      </sec>
      <sec>
        <title>EVs derived from non-parenchymal cells</title>
        <p>Non-parenchymal cells, including LSECs, Kupffer cells, lymphocytes, and HeSCs play a critical role in many liver diseases and use EVs for communication with neighbor cells during liver damage[<xref rid="B65" ref-type="bibr">65</xref>,<xref rid="B66" ref-type="bibr">66</xref>]. For instance, connective tissue growth factor (CCN2), a pro-fibrogenic mediator, is packaged into EVs produced by activated HeSCs. Then, exosome CCN2 can be delivered to other quiescent or activated HeSCs to induce trans-activation[<xref rid="B79" ref-type="bibr">79</xref>]. On the other hand, EVs derived from quiescent but not from activated HeSCs transport Twist 1 that suppress CCN2 on target cells through miR-214 induction[<xref rid="B80" ref-type="bibr">80</xref>]. Furthermore, Chen et al[<xref rid="B81" ref-type="bibr">81</xref>] showed that miR-199a-5p is loaded in quiescent HeSCs-derived EVs and also regulates CCN2 expression and activity on target cells (Figure <xref ref-type="fig" rid="F2">2</xref>). It seems to be a balance between EVs derived from active or quiescent HeSCs that promotes or inhibits liver damage. In addition, LSECs are known to maintain the HeSC quiescence through direct cell-to-cell contact and paracrine factors secretion[<xref rid="B82" ref-type="bibr">82</xref>]. Wang et al[<xref rid="B83" ref-type="bibr">83</xref>] demonstrated that LSEC-derived EVs have the ability to transfer Sphingosine kinase 1 (SK1) to regulate HeSC activation. In contrast, Ichinohe et al[<xref rid="B84" ref-type="bibr">84</xref>] demonstrated that progenitor hepatic cell-derived EVs stimulate LSECs and Kupffer cells to produce IL17B and IL25 resulting in proliferation of small progenitor hepatic cells (SPHCs) and liver regeneration (Figure <xref ref-type="fig" rid="F2">2</xref>). These findings evidence the importance of EVs derived from LSECs in affecting the activation state of neighboring cells. However, the mechanisms by which exosomes reach and attach target cells are not well understood. It has been reported that endocytosis of LSEC-derived EVs is mediated by the interaction between exosomal fibronectin and its ligand on the surface of HeSCs[<xref rid="B83" ref-type="bibr">83</xref>]. Additionally, integrin &#x3B1;v&#x3B2;3 or &#x3B1;5&#x3B2;1 and heparan sulfate proteoglycan are ligand for EVs-HeSCs interaction and allow information transfer from endothelial cells[<xref rid="B85" ref-type="bibr">85</xref>].</p>
        <p>Other important non-parenchymal cells involved in fibrogenesis are Kupffer cells and infiltrating macrophages. These cells are key players not only in fibrogenesis but also in fibrosis resolution and regeneration[<xref rid="B86" ref-type="bibr">86</xref>,<xref rid="B87" ref-type="bibr">87</xref>]. In alcoholic liver injury, hepatocyte-derived EVs enriched in miR122 sensitize macrophages to LPS and induce their production of pro-inflammatory cytokines[<xref rid="B75" ref-type="bibr">75</xref>]. Moreover, CD40L presence on hepatocyte-derived EVs during alcoholic hepatitis promotes macrophage activation and the switch to a pro-inflammatory profile[<xref rid="B88" ref-type="bibr">88</xref>,<xref rid="B89" ref-type="bibr">89</xref>]. In contrast, <italic>in vitro</italic> exposure of monocytes to alcohol increased their release of EVs, which in turn induce an anti-inflammatory M2 profile of na&#xEF;ve monocytes[<xref rid="B90" ref-type="bibr">90</xref>]. Interestingly, EVs derived from alcohol exposed monocytes contain high levels of miR-27a that is known to induce M2 polarization[<xref rid="B90" ref-type="bibr">90</xref>,<xref rid="B91" ref-type="bibr">91</xref>] (Figure <xref ref-type="fig" rid="F2">2</xref>).</p>
        <p>In summary, it has been determined that EVs play a key role on the pathophysiological response to liver damage. EVs allow the interaction between parenchymal cells and non-parenchymal cells, mainly HeSCs, Kupffer cells and LSECs, mediating their anti/pro-fibrogenic state. The role of EVs in cell-to-cell communication during liver damage and the transfer of molecules, proteins and miRNAs is gaining importance in the field. Furthermore, this mechanism can be exploited for new therapeutic approaches or used as biomarkers in non-invasive methods. In line with this, it has recently been reported that MSCs release high levels of EVs that can mediate part of their therapeutic effects. Thus, considering the key role of EVs in liver cell communication, MSC-derived EVs (MSC-EVs) could be studied as a new therapeutic approach for hepatic regeneration strategies.</p>
      </sec>
    </sec>
    <sec>
      <title>MSC-EVS AND THEIR POTENTIAL FOR LIVER REGENERATION</title>
      <p>As described above, the main mechanism by which MSCs support the repair and regeneration of injured tissues is by releasing paracrine factors[<xref rid="B7" ref-type="bibr">7</xref>]. Recently, this paracrine mechanism was described to be partially mediated by EVs released by MSCs[<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B56" ref-type="bibr">56</xref>]. <italic>In vitro</italic> assays demonstrated that MSC-EVs induce hepatocyte proliferation and dedifferentiation into progenitor oval cells[<xref rid="B92" ref-type="bibr">92</xref>,<xref rid="B93" ref-type="bibr">93</xref>]. Therapeutic effects of MSC-EVs were demonstrated in pre-clinical models of acute kidney injury[<xref rid="B94" ref-type="bibr">94</xref>], and then in pathologies of heart, brain, kidney, muscle and liver[<xref rid="B95" ref-type="bibr">95</xref>].</p>
      <p>Li et al[<xref rid="B96" ref-type="bibr">96</xref>] demonstrated that MSC-EVs reduced the degree of hepatic injury, collagen deposition and inflammation in mice with fibrosis induced by carbon tetrachloride (CCl<sub>4</sub>). The antifibrotic effect observed by MSC-EVs is mediated by the inactivation of TGF-&#x3B2;1/Smad signaling pathway. Moreover, a reversion of the epithelial-to-mesenchymal transition (EMT) both <italic>in vivo</italic> and <italic>in vitro</italic> was observed after the EV treatment[<xref rid="B96" ref-type="bibr">96</xref>] (Figure <xref ref-type="fig" rid="F2">2</xref>). Therefore, EVs derived from human MSCs were effective in mice demonstrating that they preserve at least part of the immunomodulatory properties of the cells of origin.</p>
      <p>As for liver fibrosis, the therapeutic capacity of MSC-EVs was also assessed in acute models of liver injury. Cheng et al[<xref rid="B97" ref-type="bibr">97</xref>] studied the effect of EVs derived from menstrual blood MSCs in a galactosamine/LPS mice model. MSC-EVs were able to enhance animal survival and reversion of liver failure through hepatocyte apoptosis inhibition and systemic inflammation reduction. In addition, <italic>in vitro</italic> assays showed that EVs are taken up by AML12 cells (hepatocyte cell line) resulting in the inhibition of apoptosis induced by galactosamine/LPS[<xref rid="B97" ref-type="bibr">97</xref>]. Similar results were observed by Haga et al[<xref rid="B98" ref-type="bibr">98</xref>] using EVs derived from bone marrow MSCs in an animal model of acute liver failure. A relevant finding was the preservation of the biological activity of cryopreserved-EVs m up to 3 mo, indicating the stability of EVs[<xref rid="B98" ref-type="bibr">98</xref>].</p>
      <p>It is known that induction of oxidative stress in the liver results in severe hepatic diseases by inducing cell apoptosis. A protective and proliferative effect of MSC-EVs in a lethal mice model induced by a single dose of CCl<sub>4</sub> has been reported[<xref rid="B99" ref-type="bibr">99</xref>]. In addition, MSC-EVs inhibited hepatocyte apoptosis induced by acetaminophen and H<sub>2</sub>O<sub>2</sub> and increased cell viability <italic>in vitro</italic>[<xref rid="B99" ref-type="bibr">99</xref>]. In this line, Yan et al[<xref rid="B100" ref-type="bibr">100</xref>] demonstrated that EVs derived from umbilical cord MSCs induced an antioxidant effect on hepatocytes. Glutathione peroxidase 1 (GPX1) delivered on MSC-EVs reduces the reactive oxygen species (ROS) intracellular levels and inhibits the oxidative stress-induced apoptosis <italic>in vitro</italic> and <italic>in vivo</italic>. Remarkably, authors demonstrated that a low dose of EVs (16 mg/kg of body weight) resulted in similar effects either by tail vein administration or oral gavage. In addition, Nong et al[<xref rid="B101" ref-type="bibr">101</xref>] tested the effect of EVs generated from MSC-derived Induced pluripotent stem cells (iPSCs) (MSC-iPSC-EVs) in hepatic ischemia-reperfusion (I-R) injury models. <italic>In vivo</italic> administration of MSC-iPSC-EVs in I-R injury mice model resulted in a decrease of oxidative stress response and apoptosis, and an increase of hepatocyte proliferation (Figure <xref ref-type="fig" rid="F2">2</xref>).Consistently, an amelioration of hepatic damage and inflammatory response was observed after EV treatment. It should be noted that MSC-iPSC-EVs keep the characteristics of EVs usually obtained from tissue-derived MSCs (bone marrow, adipose tissue and umbilical cord)[<xref rid="B101" ref-type="bibr">101</xref>]. In addition, it has been reported that MSC-iPSC-EVs could directly fuse with hepatocytes increasing the activity of sphingosine kinase (SK1). Moreover, the increase in SK activity will in turn increase the sphingosine-1-phosphate (S1P) levels affecting hepatocyte proliferation[<xref rid="B93" ref-type="bibr">93</xref>] (Table <xref ref-type="table" rid="T2">2</xref>).</p>
      <table-wrap id="T2" position="float">
        <label>Table 2</label>
        <caption>
          <p>Mesenchymal stem/stromal cells-derived extracellular vesicles in experimental models of liver disease</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead align="center">
            <tr>
              <td align="left" rowspan="1" colspan="1"><bold>Ref</bold>.</td>
              <td rowspan="1" colspan="1">
                <bold>EVs Isolation/characteristics</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>Experimental model</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>Protocol</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>Biological effects</bold>
              </td>
            </tr>
          </thead>
          <tbody align="center">
            <tr>
              <td align="left" rowspan="1" colspan="1">Haga et al[<xref rid="B98" ref-type="bibr">98</xref>] 2016</td>
              <td rowspan="1" colspan="1">Ultracentrifugation Size: 46-116 nm Alix<sup>+</sup> CD9<sup>+</sup>, CD81<sup>+</sup></td>
              <td rowspan="1" colspan="1">C57Bl mice. ALF, i.p. 20 mg/body DGalNAc + 0,3 mg/body TNF-&#x3B1;</td>
              <td rowspan="1" colspan="1">2 &#xD7; 10<sup>8</sup> to 2 &#xD7; 10<sup>10</sup> i.p./i.v.</td>
              <td rowspan="1" colspan="1">&#x2191; Survival, &#x2191; F4/80, &#x2191; inhibitor MMP-1 and IL-6, &#x2193; inflammation and apoptosis, &#x2193; ALT/AST, &#x2193; ALP, &#x2193; EGF, SCF, IFN-&#x3B3;, IP-10, IL-1&#x3B1;, MIP3, MCP-1/3</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Yan et al[<xref rid="B100" ref-type="bibr">100</xref>] 2016</td>
              <td rowspan="1" colspan="1">Ultracentrifugation Size: 30-100 nm CD9<sup>+</sup>, CD61<sup>+</sup>, CD63<sup>+</sup></td>
              <td rowspan="1" colspan="1">BALB/c-<sup>nu/nu</sup> mice, i.p. CCL<sub>4</sub>induced ALF, 0.15-0.35 mL/kg</td>
              <td rowspan="1" colspan="1">8, 16, and 32 mg/kg i.v./oral</td>
              <td rowspan="1" colspan="1">&#x2193; Oxidative stress and apoptosis Induces ERK1/2 phosphorylation and Bcl2 expression Inhibits IKKB/NF&#x3BA;B/casp9/3 pathway</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Tan et al[<xref rid="B99" ref-type="bibr">99</xref>] 2014</td>
              <td rowspan="1" colspan="1">TFF, 100.kDa MWCO filter Size: 55-100 nm</td>
              <td rowspan="1" colspan="1">C57BL/6 mice. CCL<sub>4</sub>-induced ALF, i.p. 0.05 mL CCL<sub>4</sub>/kg</td>
              <td rowspan="1" colspan="1">0.4 &#x3BC;g (100 &#x3BC;L) i.s.</td>
              <td rowspan="1" colspan="1">&#x2191; Cell viability: TAMH, THLE-2, and Huh-7 &#x2191; Hepatocytes proliferation &#x2193; ALT/AST &#x2193; Casp 3/7 &#x2191; antiapoptoticBcl-xL</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Chen et al[<xref rid="B97" ref-type="bibr">97</xref>] 2017</td>
              <td rowspan="1" colspan="1">Centrifugation and Exoquick-TC Size: 30-100 nm CD63<sup>+</sup> and tsg101<sup>+</sup></td>
              <td rowspan="1" colspan="1">C57BL/6 mice. ALF, i.p. D-GalNAc 800 mg/kg and LPS 50 &#x3BC;g/kg</td>
              <td rowspan="1" colspan="1">1 &#x3BC;g/&#x3BC;L i.v.</td>
              <td rowspan="1" colspan="1">&#x2191; Liver function and survival &#x2193; Apoptosis &#x2193; TNF-&#x3B1;, IL-6 and IL-1 &#x2193; Casp-3 &#x2193; Necrosis and inflammation</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Nong et al[<xref rid="B101" ref-type="bibr">101</xref>] 2016</td>
              <td rowspan="1" colspan="1">Ultracentrifugation and ultrafiltration Size: 50-60 nm CD9<sup>+</sup>, CD63<sup>+</sup> and CD81<sup>+</sup></td>
              <td rowspan="1" colspan="1">Rats I/R injury</td>
              <td rowspan="1" colspan="1">600 &#x3BC;g suspended in 400 &#x3BC;L of PBS i.v.</td>
              <td rowspan="1" colspan="1">&#x2191; GSH, GSH-PX and SOD &#x2193; AST/ALT &#x2193; TNF-&#x3B1;, IL-6 and HMGB1 &#x2193; Casp-3 and Bax</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Du et al[<xref rid="B93" ref-type="bibr">93</xref>] 2017</td>
              <td rowspan="1" colspan="1">Centrifugation and filtered by 0, 45-&#x3BC;m PVDF filter ExoQuick Size: 100-200 nm Alix<sup>+</sup>, CD63<sup>+</sup> and CD81<sup>+</sup></td>
              <td rowspan="1" colspan="1">C57 mice I/R injury</td>
              <td rowspan="1" colspan="1">2.5 &#xD7; 10<sup>12</sup> particles in 500 &#x3BC;L of PBS i.v.</td>
              <td rowspan="1" colspan="1">&#x2191; Hepatocytes proliferation &#x2191; SK activity and S1P formation. Hepatoprotective and proliferative effect abolished by the inhibition of SK or S1P receptor 1</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>i.p.: Intraperitoneal injection; i.v.: Intravenous injection; i.s.: Intrasplenic; MMP: Metalloproteinases; CCL<sub>4</sub>: Corbon tetrachloride; D-GalNAc: N Acetylgalactosamine; IL: Interleukins; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; EGF: Epidermal growth factor; SCF: Stem cell factor; TNF: Tumor necrosis factor; IFN: Interferon; IP: Inducible protein; MIP: Macrophage inflammatory protein; MCP: Monocyte chemotactic protein; ERK: Extracellular signal-regulated kinase; Bcl: B-cell lymphoma; TFF: Tangential flow filtration; MWCO: Molecular weight cut-off; ALF: Acute liver failure; TAMH: Transgenic mouse hepatocyte; THLE: T-antigen immortalized human liver epithelial; Casp: Caspase; GSH: Glutathione; GSH-PX: Glutathione peroxidase; SOD: Superoxide dismutase; HMGB: High mobility group box; PBS: Phosphate-buffered saline; SK: Sphingosine kinase; S1P: Sphingosine 1-phosphate.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Although there is a great therapeutic potential of MSC-EVs in liver protection and regeneration, it is mandatory to understand the mechanisms involved in their biological effects. One key point of research is to know the bio distribution of EVs after systemic administration <italic>in vivo</italic>. <italic>In vitro</italic> assays showed that EVs are taken up <italic>via</italic> integrin mediated endocytosis by target liver cells[<xref rid="B67" ref-type="bibr">67</xref>,<xref rid="B85" ref-type="bibr">85</xref>,<xref rid="B90" ref-type="bibr">90</xref>,<xref rid="B97" ref-type="bibr">97</xref>]. In addition, MSC-EV biodistribution after intravenous (IV) administration shows EVs uptake as fast as 3 to 6 h after injection in liver, spleen and lung cells[<xref rid="B97" ref-type="bibr">97</xref>]. Furthermore, Haga et al[<xref rid="B98" ref-type="bibr">98</xref>] reported that liver, spleen and lung from mice with fulminant hepatitis exert a higher uptake of MSC-EVs in comparison with organs from healthy mice. However, since these experiments have been carried out using lipophilic tracers, confirmation of these results with specific markers is necessary. The MSC-EV survival in circulation after being administered and the recognition pathways used by the target cells need to be studied in depth. Moreover, this knowledge could help to define the better scheme of doses, the time of treatment and the route of administration depending of the type of liver damage. In addition, conformation details of proteins and nucleic acids loaded in the EVs is required.</p>
    </sec>
    <sec>
      <title>ENGINEERING MSC-EVS FOR LIVER REGENERATION</title>
      <p>Recently, an increased interest has been shown by the research community to improve the efficiency and potency of EVs loading specific cargos[<xref rid="B102" ref-type="bibr">102</xref>]. As described above, the EVs produced by MSCs have useful properties that would allow them to be used as therapies in different liver pathologies[<xref rid="B62" ref-type="bibr">62</xref>], and advances in nanomedicine would allow to improve the technology to generate more effective EVs[<xref rid="B102" ref-type="bibr">102</xref>,<xref rid="B103" ref-type="bibr">103</xref>]. Thereby, engineered EVs can be generated with strategies based on covalent surface chemistry, hydrophobic insertions or membrane permeabilization. Moreover, modification of the parental cells through metabolic labeling, genetic modification or by insertion of exogenous material could also produce modified EVs. These engineered EVs could carry specific DNAs, mRNAs or non-coding RNAs to the specific cell[<xref rid="B102" ref-type="bibr">102</xref>].</p>
      <p>Lou et al[<xref rid="B104" ref-type="bibr">104</xref>] demonstrated that miRNA-122 expression in MSCs by lentiviral infection increased their therapeutic effect in a fibrosis model in mice. MiR-122 positively regulates proliferation and trans differentiation of HeSCs having an important role in liver fibrogenesis[<xref rid="B105" ref-type="bibr">105</xref>]. Authors demonstrated that <italic>in vitro</italic> miRNA-122 is transferred to HeSCs through MSC-EVs resulting in the regulation of genes involved in collagen maturation and cell proliferation[<xref rid="B104" ref-type="bibr">104</xref>]. Another strategy uses EVs derived from MSCs with transient expression of miRNA-181-5p as a therapeutic option in a liver fibrosis model[<xref rid="B106" ref-type="bibr">106</xref>]. As for miRNA-122, miRNA-181-5p was delivered by MSC-EVs reducing the fibrosis and the inflammatory state of fibrotic mice[<xref rid="B106" ref-type="bibr">106</xref>]. Moreover, <italic>in vitro</italic> experiments show that after reaching the target cell, miRNA-181-5p binds to3&#xB4;-UTR of STAT3 and Bcl-2, which in turn down regulates TGF-&#x3B2;1 expression and induces autophagy in HeSCs[<xref rid="B106" ref-type="bibr">106</xref>]. Finally, in a model of autoimmune hepatitis, a cytoprotective effect of MSC-EVs engineered to charge miRNA-223 was observed. The <italic>in vitro</italic> experiments demonstrated that miRNA-223 levels were increased in hepatocytes after their incubation with the engineered EVs[<xref rid="B107" ref-type="bibr">107</xref>]. Similar results were observed <italic>in vivo</italic> with an increase of this miRNA in the liver and a reduction of its target gene NLRP3, and therefore a decrease in hepatocyte apoptosis[<xref rid="B107" ref-type="bibr">107</xref>] (Figure <xref ref-type="fig" rid="F2">2</xref>).</p>
      <p>In summary, more information is needed not only to develop more efficient therapies for liver diseases based on MSC-EVs but also to engineer them to increase their efficacy and potency.</p>
    </sec>
    <sec>
      <title>CONCLUSION</title>
      <p>MSCs-based therapy has emerged as a potent and innovative treatment for acute and chronic liver diseases. The safety and feasibility observed in the early clinical trials using MSCs have increased the interest to translate the use of these cells to the clinic. Moreover, pro-regenerative results and an improvement in the life quality of patients were observed. In ALF, MSCs could have a role decreasing liver damage progression due their immunomodulatory properties. In chronic liver diseases, MSCs could contribute to decrease liver damage and to ameliorate the degree of fibrosis. Even more, in both case MSC treatment could not only delay the transplant but also to avoid it in some particular cases. In addition, in the post-transplant setting, MSC therapy could extend the graft survival and/or decrease the amount of immunosuppression required. Although the main mechanism by which MSCs support the repair and regeneration of injured livers is by releasing paracrine factors, strong evidences demonstrated that this paracrine mechanism is mediated by EVs released by MSCs. Therefore, due to EVs&#x2019; stability for long periods of time and easy isolation methods they have become a therapeutic option to MSCs treatments in liver diseases. At present, EVs are strongly explored for therapeutic or diagnostic application, and more information is needed to develop more efficient tools for liver diseases based on MSC-EVs. However, it is important to understand that therapeutic potential of MSCs or its EVs is still a matter of debate. In addition, standardization of source of MSCs, culture conditions, pre-condition protocols for cell transplantation, administration route, doses and time of treatment is required. Nevertheless, considering that development of new therapeutic approaches for liver diseases is urgent, MSCs emerge as potent innovation. Thus, take advantage of the therapeutic potential of MSCs as promising tool for liver regeneration could attend to an important worldwide human health problem.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>Manuscript source: Invited manuscript</p>
      </fn>
      <fn>
        <p>Specialty type: Gastroenterology and hepatology</p>
      </fn>
      <fn>
        <p>Country of origin: Argentina</p>
      </fn>
      <fn>
        <p>Peer-review report classification</p>
      </fn>
      <fn>
        <p>Grade A (Excellent): A</p>
      </fn>
      <fn>
        <p>Grade B (Very good): B</p>
      </fn>
      <fn>
        <p>Grade C (Good): 0</p>
      </fn>
      <fn>
        <p>Grade D (Fair): D</p>
      </fn>
      <fn>
        <p>Grade E (Poor): 0</p>
      </fn>
      <fn fn-type="COI-statement">
        <p>Conflict-of-interest statement: The authors indicate no potential conflicts of interest.</p>
      </fn>
      <fn>
        <p>Peer-review started: April 13, 2018</p>
      </fn>
      <fn>
        <p>First decision: April 27, 2018</p>
      </fn>
      <fn>
        <p>Article in press: June 2, 2018</p>
      </fn>
      <fn>
        <p>P- Reviewer: Miloso M, Musumeci G, Scarf&#xEC; S S- Editor: Wang XJ L- Editor: A E- Editor: Huang Y</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Friedman</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of hepatic fibrogenesis</article-title>
          <source>Gastroenterology</source>
          <year>2008</year>
          <volume>134</volume>
          <fpage>1655</fpage>
          <lpage>1669</lpage>
          <pub-id pub-id-type="pmid">18471545</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>YA</given-names>
            </name>
            <name>
              <surname>Wallace</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
          <article-title>Pathobiology of liver fibrosis: a translational success story</article-title>
          <source>Gut</source>
          <year>2015</year>
          <volume>64</volume>
          <fpage>830</fpage>
          <lpage>841</lpage>
          <pub-id pub-id-type="pmid">25681399</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stravitz</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Kramer</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Management of acute liver failure</article-title>
          <source>Nat Rev Gastroenterol Hepatol</source>
          <year>2009</year>
          <volume>6</volume>
          <fpage>542</fpage>
          <lpage>553</lpage>
          <pub-id pub-id-type="pmid">19652652</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trovato</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Catalano</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Musumeci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Trovato</surname>
              <given-names>GM</given-names>
            </name>
          </person-group>
          <article-title>4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics</article-title>
          <source>EPMA J</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>21</fpage>
          <pub-id pub-id-type="pmid">25937854</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trovato</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Martines</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Brischetto</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Catalano</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Musumeci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Trovato</surname>
              <given-names>GM</given-names>
            </name>
          </person-group>
          <article-title>Fatty liver disease and lifestyle in youngsters: diet, food intake frequency, exercise, sleep shortage and fashion</article-title>
          <source>Liver Int</source>
          <year>2016</year>
          <volume>36</volume>
          <fpage>427</fpage>
          <lpage>433</lpage>
          <pub-id pub-id-type="pmid">26346413</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aquino</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Bolontrade</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Garc&#xED;a</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Podhajcer</surname>
              <given-names>OL</given-names>
            </name>
            <name>
              <surname>Mazzolini</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma</article-title>
          <source>Gene Ther</source>
          <year>2010</year>
          <volume>17</volume>
          <fpage>692</fpage>
          <lpage>708</lpage>
          <pub-id pub-id-type="pmid">20220785</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fiore</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Mazzolini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Aquino</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
          <article-title>Mesenchymal Stem/Stromal Cells in Liver Fibrosis: Recent Findings, Old/New Caveats and Future Perspectives</article-title>
          <source>Stem Cell Rev</source>
          <year>2015</year>
          <volume>11</volume>
          <fpage>586</fpage>
          <lpage>597</lpage>
          <pub-id pub-id-type="pmid">25820543</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Bayo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bolontrade</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Sganga</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Malvicini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alaniz</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Aquino</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Fiore</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rizzo</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo</article-title>
          <source>Mol Pharm</source>
          <year>2011</year>
          <volume>8</volume>
          <fpage>1538</fpage>
          <lpage>1548</lpage>
          <pub-id pub-id-type="pmid">21770423</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Volarevic</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Nurkovic</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Arsenijevic</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Stojkovic</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Concise review: Therapeutic potential of mesenchymal stem cells for the treatment of acute liver failure and cirrhosis</article-title>
          <source>Stem Cells</source>
          <year>2014</year>
          <volume>32</volume>
          <fpage>2818</fpage>
          <lpage>2823</lpage>
          <pub-id pub-id-type="pmid">25154380</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Camussi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Deregibus</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Cantaluppi</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Role of stem-cell-derived microvesicles in the paracrine action of stem cells</article-title>
          <source>Biochem Soc Trans</source>
          <year>2013</year>
          <volume>41</volume>
          <fpage>283</fpage>
          <lpage>287</lpage>
          <pub-id pub-id-type="pmid">23356298</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Squillaro</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Peluso</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Galderisi</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Clinical Trials With Mesenchymal Stem Cells: An Update</article-title>
          <source>Cell Transplant</source>
          <year>2016</year>
          <volume>25</volume>
          <fpage>829</fpage>
          <lpage>848</lpage>
          <pub-id pub-id-type="pmid">26423725</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mobasheri</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kalamegam</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Musumeci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Batt</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Chondrocyte and mesenchymal stem cell-based therapies for cartilage repair in osteoarthritis and related orthopaedic conditions</article-title>
          <source>Maturitas</source>
          <year>2014</year>
          <volume>78</volume>
          <fpage>188</fpage>
          <lpage>198</lpage>
          <pub-id pub-id-type="pmid">24855933</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsuchiya</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kojima</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ikarashi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Seino</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kawata</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Terai</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases</article-title>
          <source>Inflamm Regen</source>
          <year>2017</year>
          <volume>37</volume>
          <fpage>16</fpage>
          <pub-id pub-id-type="pmid">29259715</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mohamadnejad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alimoghaddam</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mohyeddin-Bonab</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bagheri</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bashtar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ghanaati</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Baharvand</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ghavamzadeh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Malekzadeh</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis</article-title>
          <source>Arch Iran Med</source>
          <year>2007</year>
          <volume>10</volume>
          <fpage>459</fpage>
          <lpage>466</lpage>
          <pub-id pub-id-type="pmid">17903050</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kharaziha</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hellstr&#xF6;m</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Noorinayer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Farzaneh</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Aghajani</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Jafari</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Telkabadi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Atashi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Honardoost</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zali</surname>
              <given-names>MR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial</article-title>
          <source>Eur J Gastroenterol Hepatol</source>
          <year>2009</year>
          <volume>21</volume>
          <fpage>1199</fpage>
          <lpage>1205</lpage>
          <pub-id pub-id-type="pmid">19455046</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>El-Ansary M</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Abdel-Aziz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Abdel-Hamid</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Phase I Trial: Mesenchymal Stem Cells Transplantation in End Stage Liver Disease</article-title>
          <source>Journal of American Science</source>
          <year>2010</year>
          <volume>6</volume>
          <fpage>1</fpage>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>El-Ansary</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Abdel-Aziz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Mogawer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Abdel-Hamid</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hammam</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Teaema</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wahdan</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis</article-title>
          <source>Stem Cell Rev</source>
          <year>2012</year>
          <volume>8</volume>
          <fpage>972</fpage>
          <lpage>981</lpage>
          <pub-id pub-id-type="pmid">21989829</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lv</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lv</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients</article-title>
          <source>J Gastroenterol Hepatol</source>
          <year>2012</year>
          <volume>27 Suppl 2</volume>
          <fpage>112</fpage>
          <lpage>120</lpage>
          <pub-id pub-id-type="pmid">22320928</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zou</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lv</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients</article-title>
          <source>Stem Cells Transl Med</source>
          <year>2012</year>
          <volume>1</volume>
          <fpage>725</fpage>
          <lpage>731</lpage>
          <pub-id pub-id-type="pmid">23197664</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mohamadnejad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alimoghaddam</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bagheri</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ashrafi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Abdollahzadeh</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Akhlaghpoor</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bashtar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ghavamzadeh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Malekzadeh</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis</article-title>
          <source>Liver Int</source>
          <year>2013</year>
          <volume>33</volume>
          <fpage>1490</fpage>
          <lpage>1496</lpage>
          <pub-id pub-id-type="pmid">23763455</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lv</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis</article-title>
          <source>J Gastroenterol Hepatol</source>
          <year>2013</year>
          <volume>28 Suppl 1</volume>
          <fpage>85</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="pmid">23855301</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shan</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>YZ</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis</article-title>
          <source>Stem Cells Dev</source>
          <year>2014</year>
          <volume>23</volume>
          <fpage>2482</fpage>
          <lpage>2489</lpage>
          <pub-id pub-id-type="pmid">24835895</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Salama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zekri</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Medhat</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Al Alim</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>OS</given-names>
            </name>
            <name>
              <surname>Bahnassy</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Lotfy</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Musa</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease</article-title>
          <source>Stem Cell Res Ther</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>70</fpage>
          <pub-id pub-id-type="pmid">24886681</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>GY</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Yi</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yi</surname>
              <given-names>SH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Therapeutic potentials of umbilical cord-derived mesenchymal stromal cells for ischemic-type biliary lesions following liver transplantation</article-title>
          <source>Cytotherapy</source>
          <year>2017</year>
          <volume>19</volume>
          <fpage>194</fpage>
          <lpage>199</lpage>
          <pub-id pub-id-type="pmid">27964826</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Detry</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Vandermeulen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Delbouille</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Somja</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bletard</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Briquet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lechanteur</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Giet</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Baudoux</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hannon</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study</article-title>
          <source>J Hepatol</source>
          <year>2017</year>
          <volume>67</volume>
          <fpage>47</fpage>
          <lpage>55</lpage>
          <pub-id pub-id-type="pmid">28284916</pub-id>
        </element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Meng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A Pilot Study of Mesenchymal Stem Cell Therapy for Acute Liver Allograft Rejection</article-title>
          <source>Stem Cells Transl Med</source>
          <year>2017</year>
          <volume>6</volume>
          <fpage>2053</fpage>
          <lpage>2061</lpage>
          <pub-id pub-id-type="pmid">29178564</pub-id>
        </element-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hartleif</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schumm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>D&#xF6;ring</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mezger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dahlke</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Riethm&#xFC;ller</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>K&#xF6;nigsrainer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Handgretinger</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nadalin</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety and Tolerance of Donor-Derived Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation: The MYSTEP1 Study</article-title>
          <source>Stem Cells Int</source>
          <year>2017</year>
          <volume>2017</volume>
          <fpage>2352954</fpage>
          <pub-id pub-id-type="pmid">28740511</pub-id>
        </element-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>DY</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>XY</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>QL</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Mei</surname>
              <given-names>YY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial</article-title>
          <source>Hepatology</source>
          <year>2017</year>
          <volume>66</volume>
          <fpage>209</fpage>
          <lpage>219</lpage>
          <pub-id pub-id-type="pmid">28370357</pub-id>
        </element-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>DY</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>YB</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>ZL</given-names>
            </name>
          </person-group>
          <article-title>Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes</article-title>
          <source>Hepatology</source>
          <year>2011</year>
          <volume>54</volume>
          <fpage>820</fpage>
          <lpage>828</lpage>
          <pub-id pub-id-type="pmid">21608000</pub-id>
        </element-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jang</surname>
              <given-names>YO</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Baik</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>MY</given-names>
            </name>
            <name>
              <surname>Eom</surname>
              <given-names>YW</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>MY</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study</article-title>
          <source>Liver Int</source>
          <year>2014</year>
          <volume>34</volume>
          <fpage>33</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="pmid">23782511</pub-id>
        </element-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gong</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hou</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg/Th17 cells</article-title>
          <source>J Gastroenterol Hepatol</source>
          <year>2014</year>
          <volume>29</volume>
          <fpage>1620</fpage>
          <lpage>1628</lpage>
          <pub-id pub-id-type="pmid">24942592</pub-id>
        </element-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suk</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Yoon</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>MY</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial</article-title>
          <source>Hepatology</source>
          <year>2016</year>
          <volume>64</volume>
          <fpage>2185</fpage>
          <lpage>2197</lpage>
          <pub-id pub-id-type="pmid">27339398</pub-id>
        </element-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sakai Y</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Seki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sunagozaka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Terashima</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Komura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Miyazawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kawaguchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nasti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mochida</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phase I clinical study of liver regenerative therapy for cirrhosis by intrahepatic arterial infusion of freshly isolated autologous adipose tissue-derived stromal/stem (regenerative) cell Reg</article-title>
          <source>Ther</source>
          <year>2017</year>
          <volume>6</volume>
          <fpage>52</fpage>
          <lpage>64</lpage>
        </element-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amer</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>El-Sayed</surname>
              <given-names>SZ</given-names>
            </name>
            <name>
              <surname>El-Kheir</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Gabr</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gomaa</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>El-Noomani</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hegazy</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells</article-title>
          <source>Eur J Gastroenterol Hepatol</source>
          <year>2011</year>
          <volume>23</volume>
          <fpage>936</fpage>
          <lpage>941</lpage>
          <pub-id pub-id-type="pmid">21900788</pub-id>
        </element-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amin</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Sabry</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rashed</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Aref</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>el-Ghobary</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Farhan</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Fouad</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Youssef</surname>
              <given-names>YA</given-names>
            </name>
          </person-group>
          <article-title>Short-term evaluation of autologous transplantation of bone marrow-derived mesenchymal stem cells in patients with cirrhosis: Egyptian study</article-title>
          <source>Clin Transplant</source>
          <year>2013</year>
          <volume>27</volume>
          <fpage>607</fpage>
          <lpage>612</lpage>
          <pub-id pub-id-type="pmid">23923970</pub-id>
        </element-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bayo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Marrod&#xE1;n</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Aquino</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Garc&#xED;a</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Mazzolini</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>The therapeutic potential of bone marrow-derived mesenchymal stromal cells on hepatocellular carcinoma</article-title>
          <source>Liver Int</source>
          <year>2014</year>
          <volume>34</volume>
          <fpage>330</fpage>
          <lpage>342</lpage>
          <pub-id pub-id-type="pmid">24112437</pub-id>
        </element-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Usunier</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Benderitter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tamarat</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chapel</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Management of fibrosis: the mesenchymal stromal cells breakthrough</article-title>
          <source>Stem Cells Int</source>
          <year>2014</year>
          <volume>2014</volume>
          <fpage>340257</fpage>
          <pub-id pub-id-type="pmid">25132856</pub-id>
        </element-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bayo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fiore</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Aquino</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Malvicini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rizzo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Peixoto</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Andriani</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Alaniz</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Piccioni</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bolontrade</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased migration of human mesenchymal stromal cells by autocrine motility factor (AMF) resulted in enhanced recruitment towards hepatocellular carcinoma</article-title>
          <source>PLoS One</source>
          <year>2014</year>
          <volume>9</volume>
          <fpage>e95171</fpage>
          <pub-id pub-id-type="pmid">24736611</pub-id>
        </element-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bayo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Real</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fiore</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Malvicini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sganga</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bolontrade</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Andriani</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Bizama</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fresno</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Podhajcer</surname>
              <given-names>O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>IL-8, GRO and MCP-1 produced by hepatocellular carcinoma microenvironment determine the migratory capacity of human bone marrow-derived mesenchymal stromal cells without affecting tumor aggressiveness</article-title>
          <source>Oncotarget</source>
          <year>2016</year>
          <volume>8</volume>
          <fpage>80235</fpage>
          <lpage>80248</lpage>
          <pub-id pub-id-type="pmid">29113298</pub-id>
        </element-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bataller</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Brenner</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Liver fibrosis</article-title>
          <source>J Clin Invest</source>
          <year>2005</year>
          <volume>115</volume>
          <fpage>209</fpage>
          <lpage>218</lpage>
          <pub-id pub-id-type="pmid">15690074</pub-id>
        </element-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuroda</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kitada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wakao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dezawa</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Bone marrow mesenchymal cells: how do they contribute to tissue repair and are they really stem cells?</article-title>
          <source>Arch Immunol Ther Exp (Warsz)</source>
          <year>2011</year>
          <volume>59</volume>
          <fpage>369</fpage>
          <lpage>378</lpage>
          <pub-id pub-id-type="pmid">21789625</pub-id>
        </element-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gardner</surname>
              <given-names>OFW</given-names>
            </name>
            <name>
              <surname>Musumeci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Neumann</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Eglin</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Archer</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Alini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stoddart</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Asymmetrical seeding of MSCs into fibrin-poly(ester-urethane) scaffolds and its effect on mechanically induced chondrogenesis</article-title>
          <source>J Tissue Eng Regen Med</source>
          <year>2017</year>
          <volume>11</volume>
          <fpage>2912</fpage>
          <lpage>2921</lpage>
          <pub-id pub-id-type="pmid">27406210</pub-id>
        </element-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Musumeci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lo Furno</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Loreto</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Giuffrida</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Caggia</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Leonardi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cardile</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Mesenchymal stem cells from adipose tissue which have been differentiated into chondrocytes in three-dimensional culture express lubricin</article-title>
          <source>Exp Biol Med (Maywood)</source>
          <year>2011</year>
          <volume>236</volume>
          <fpage>1333</fpage>
          <lpage>1341</lpage>
          <pub-id pub-id-type="pmid">22036733</pub-id>
        </element-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pittenger</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Mackay</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Jaiswal</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Douglas</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mosca</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Moorman</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Simonetti</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Craig</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Marshak</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Multilineage potential of adult human mesenchymal stem cells</article-title>
          <source>Science</source>
          <year>1999</year>
          <volume>284</volume>
          <fpage>143</fpage>
          <lpage>147</lpage>
          <pub-id pub-id-type="pmid">10102814</pub-id>
        </element-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meier</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>M&#xFC;ller</surname>
              <given-names>YD</given-names>
            </name>
            <name>
              <surname>Morel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gonelle-Gispert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>B&#xFC;hler</surname>
              <given-names>LH</given-names>
            </name>
          </person-group>
          <article-title>Transplantation of mesenchymal stem cells for the treatment of liver diseases, is there enough evidence?</article-title>
          <source>Stem Cell Res</source>
          <year>2013</year>
          <volume>11</volume>
          <fpage>1348</fpage>
          <lpage>1364</lpage>
          <pub-id pub-id-type="pmid">24090934</pub-id>
        </element-citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Xin</surname>
              <given-names>ZC</given-names>
            </name>
            <name>
              <surname>Dai</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lue</surname>
              <given-names>TF</given-names>
            </name>
          </person-group>
          <article-title>Commonly used mesenchymal stem cell markers and tracking labels: Limitations and challenges</article-title>
          <source>Histol Histopathol</source>
          <year>2013</year>
          <volume>28</volume>
          <fpage>1109</fpage>
          <lpage>1116</lpage>
          <pub-id pub-id-type="pmid">23588700</pub-id>
        </element-citation>
      </ref>
      <ref id="B47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reagan</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <article-title>Concise review: Mesenchymal stem cell tumor-homing: detection methods in disease model systems</article-title>
          <source>Stem Cells</source>
          <year>2011</year>
          <volume>29</volume>
          <fpage>920</fpage>
          <lpage>927</lpage>
          <pub-id pub-id-type="pmid">21557390</pub-id>
        </element-citation>
      </ref>
      <ref id="B48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fiore</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Bayo</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Malvicini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lloyd</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Piccioni</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rizzo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Peixoto</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sola</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Atorrasagasti</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mesenchymal stromal cells engineered to produce IGF-I by recombinant adenovirus ameliorate liver fibrosis in mice</article-title>
          <source>Stem Cells Dev</source>
          <year>2015</year>
          <volume>24</volume>
          <fpage>791</fpage>
          <lpage>801</lpage>
          <pub-id pub-id-type="pmid">25315017</pub-id>
        </element-citation>
      </ref>
      <ref id="B49">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dai</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Guan</surname>
              <given-names>LX</given-names>
            </name>
            <name>
              <surname>Ritchie</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>JX</given-names>
            </name>
          </person-group>
          <article-title>The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis</article-title>
          <source>Stem Cell Res</source>
          <year>2009</year>
          <volume>2</volume>
          <fpage>16</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="pmid">19383405</pub-id>
        </element-citation>
      </ref>
      <ref id="B50">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sato</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Araki</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kawano</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kobune</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Miyanishi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takayama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>106</volume>
          <fpage>756</fpage>
          <lpage>763</lpage>
          <pub-id pub-id-type="pmid">15817682</pub-id>
        </element-citation>
      </ref>
      <ref id="B51">
        <label>51</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meirelles Lda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fontes</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Covas</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Caplan</surname>
              <given-names>AI</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms involved in the therapeutic properties of mesenchymal stem cells</article-title>
          <source>Cytokine Growth Factor Rev</source>
          <year>2009</year>
          <volume>20</volume>
          <fpage>419</fpage>
          <lpage>427</lpage>
          <pub-id pub-id-type="pmid">19926330</pub-id>
        </element-citation>
      </ref>
      <ref id="B52">
        <label>52</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Tao</surname>
              <given-names>XR</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>YB</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>XM</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>JX</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>JT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Isolation and characterization of bipotent liver progenitor cells from adult mouse</article-title>
          <source>Stem Cells</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>322</fpage>
          <lpage>332</lpage>
          <pub-id pub-id-type="pmid">16109753</pub-id>
        </element-citation>
      </ref>
      <ref id="B53">
        <label>53</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chiu</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>van de Ven</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gaarde</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Deleve</surname>
              <given-names>LD</given-names>
            </name>
          </person-group>
          <article-title>Hepatic vascular endothelial growth factor regulates recruitment of rat liver sinusoidal endothelial cell progenitor cells</article-title>
          <source>Gastroenterology</source>
          <year>2012</year>
          <volume>143</volume>
          <fpage>1555</fpage>
          <lpage>1563.e2</lpage>
          <pub-id pub-id-type="pmid">22902870</pub-id>
        </element-citation>
      </ref>
      <ref id="B54">
        <label>54</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parekkadan</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>van Poll</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Suganuma</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Berthiaume</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tilles</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Yarmush</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
          <article-title>Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure</article-title>
          <source>PLoS One</source>
          <year>2007</year>
          <volume>2</volume>
          <fpage>e941</fpage>
          <pub-id pub-id-type="pmid">17895982</pub-id>
        </element-citation>
      </ref>
      <ref id="B55">
        <label>55</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Poll</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Parekkadan</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Berthiaume</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Nahmias</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tilles</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Yarmush</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
          <article-title>Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo</article-title>
          <source>Hepatology</source>
          <year>2008</year>
          <volume>47</volume>
          <fpage>1634</fpage>
          <lpage>1643</lpage>
          <pub-id pub-id-type="pmid">18395843</pub-id>
        </element-citation>
      </ref>
      <ref id="B56">
        <label>56</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Exosomes derived from mesenchymal stem cells</article-title>
          <source>Int J Mol Sci</source>
          <year>2014</year>
          <volume>15</volume>
          <fpage>4142</fpage>
          <lpage>4157</lpage>
          <pub-id pub-id-type="pmid">24608926</pub-id>
        </element-citation>
      </ref>
      <ref id="B57">
        <label>57</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ha</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nadithe</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges</article-title>
          <source>Acta Pharm Sin B</source>
          <year>2016</year>
          <volume>6</volume>
          <fpage>287</fpage>
          <lpage>296</lpage>
          <pub-id pub-id-type="pmid">27471669</pub-id>
        </element-citation>
      </ref>
      <ref id="B58">
        <label>58</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Th&#xE9;ry</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zitvogel</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Amigorena</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Exosomes: composition, biogenesis and function</article-title>
          <source>Nat Rev Immunol</source>
          <year>2002</year>
          <volume>2</volume>
          <fpage>569</fpage>
          <lpage>579</lpage>
          <pub-id pub-id-type="pmid">12154376</pub-id>
        </element-citation>
      </ref>
      <ref id="B59">
        <label>59</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>L&#xF6;tvall</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Hochberg</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Buz&#xE1;s</surname>
              <given-names>EI</given-names>
            </name>
            <name>
              <surname>Di Vizio</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gardiner</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gho</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Kurochkin</surname>
              <given-names>IV</given-names>
            </name>
            <name>
              <surname>Mathivanan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Quesenberry</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles</article-title>
          <source>J Extracell Vesicles</source>
          <year>2014</year>
          <volume>3</volume>
          <fpage>26913</fpage>
          <pub-id pub-id-type="pmid">25536934</pub-id>
        </element-citation>
      </ref>
      <ref id="B60">
        <label>60</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maumus</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jorgensen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>No&#xEB;l</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Mesenchymal stem cells in regenerative medicine applied to rheumatic diseases: role of secretome and exosomes</article-title>
          <source>Biochimie</source>
          <year>2013</year>
          <volume>95</volume>
          <fpage>2229</fpage>
          <lpage>2234</lpage>
          <pub-id pub-id-type="pmid">23685070</pub-id>
        </element-citation>
      </ref>
      <ref id="B61">
        <label>61</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Exosomes in mesenchymal stem cells, a new therapeutic strategy for cardiovascular diseases?</article-title>
          <source>Int J Biol Sci</source>
          <year>2015</year>
          <volume>11</volume>
          <fpage>238</fpage>
          <lpage>245</lpage>
          <pub-id pub-id-type="pmid">25632267</pub-id>
        </element-citation>
      </ref>
      <ref id="B62">
        <label>62</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>B&#xF6;rger</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bremer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ferrer-Tur</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gockeln</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Stambouli</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Becic</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Giebel</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles and Their Potential as Novel Immunomodulatory Therapeutic Agents</article-title>
          <source>Int J Mol Sci</source>
          <year>2017</year>
          <fpage>18</fpage>
        </element-citation>
      </ref>
      <ref id="B63">
        <label>63</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tomiyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>GX</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Okazaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>XS</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>Q</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis</article-title>
          <source>Cell Mol Immunol</source>
          <year>2017</year>
          <volume>14</volume>
          <fpage>276</fpage>
          <lpage>284</lpage>
          <pub-id pub-id-type="pmid">26388238</pub-id>
        </element-citation>
      </ref>
      <ref id="B64">
        <label>64</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fornari</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ferracin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Trer&#xE8;</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Milazzo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Marinelli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Galassi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Venerandi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pollutri</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Patrizi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Borghi</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC</article-title>
          <source>PLoS One</source>
          <year>2015</year>
          <volume>10</volume>
          <fpage>e0141448</fpage>
          <pub-id pub-id-type="pmid">26509672</pub-id>
        </element-citation>
      </ref>
      <ref id="B65">
        <label>65</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maji</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Matsuda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>IK</given-names>
            </name>
            <name>
              <surname>Parasramka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Extracellular vesicles in liver diseases</article-title>
          <source>Am J Physiol Gastrointest Liver Physiol</source>
          <year>2017</year>
          <volume>312</volume>
          <fpage>G194</fpage>
          <lpage>G200</lpage>
          <pub-id pub-id-type="pmid">28039157</pub-id>
        </element-citation>
      </ref>
      <ref id="B66">
        <label>66</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Szabo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Momen-Heravi</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets</article-title>
          <source>Nat Rev Gastroenterol Hepatol</source>
          <year>2017</year>
          <volume>14</volume>
          <fpage>455</fpage>
          <lpage>466</lpage>
          <pub-id pub-id-type="pmid">28634412</pub-id>
        </element-citation>
      </ref>
      <ref id="B67">
        <label>67</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nojima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Schuster</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Japtok</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kleuser</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Gulbins</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lentsch</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Hepatocyte exosomes mediate liver repair and regeneration via sphingosine-1-phosphate</article-title>
          <source>J Hepatol</source>
          <year>2016</year>
          <volume>64</volume>
          <fpage>60</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="pmid">26254847</pub-id>
        </element-citation>
      </ref>
      <ref id="B68">
        <label>68</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Herrera</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Fonsato</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Gatti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Deregibus</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Sordi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cantarella</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Calogero</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bussolati</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tetta</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Camussi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Human liver stem cell-derived microvesicles accelerate hepatic regeneration in hepatectomized rats</article-title>
          <source>J Cell Mol Med</source>
          <year>2010</year>
          <volume>14</volume>
          <fpage>1605</fpage>
          <lpage>1618</lpage>
          <pub-id pub-id-type="pmid">19650833</pub-id>
        </element-citation>
      </ref>
      <ref id="B69">
        <label>69</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fatima</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ekstrom</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nazarenko</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Maugeri</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Valadi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Camussi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Nawaz</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Non-coding RNAs in Mesenchymal Stem Cell-Derived Extracellular Vesicles: Deciphering Regulatory Roles in Stem Cell Potency, Inflammatory Resolve, and Tissue Regeneration</article-title>
          <source>Front Genet</source>
          <year>2017</year>
          <volume>8</volume>
          <fpage>161</fpage>
          <pub-id pub-id-type="pmid">29123544</pub-id>
        </element-citation>
      </ref>
      <ref id="B70">
        <label>70</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Abdelmohsen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mustapic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kapogiannis</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gorospe</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>RNA in extracellular vesicles</article-title>
          <source>Wiley Interdiscip Rev RNA</source>
          <year>2017</year>
          <fpage>8</fpage>
        </element-citation>
      </ref>
      <ref id="B71">
        <label>71</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nojima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Konishi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Schuster</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Japtok</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kleuser</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Gulbins</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lentsch</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Chemokine Receptors, CXCR1 and CXCR2, Differentially Regulate Exosome Release in Hepatocytes</article-title>
          <source>PLoS One</source>
          <year>2016</year>
          <volume>11</volume>
          <fpage>e0161443</fpage>
          <pub-id pub-id-type="pmid">27551720</pub-id>
        </element-citation>
      </ref>
      <ref id="B72">
        <label>72</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hirsova</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ibrahim</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Krishnan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>VK</given-names>
            </name>
            <name>
              <surname>Bronk</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Werneburg</surname>
              <given-names>NW</given-names>
            </name>
            <name>
              <surname>Charlton</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>VH</given-names>
            </name>
            <name>
              <surname>Malhi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gores</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes</article-title>
          <source>Gastroenterology</source>
          <year>2016</year>
          <volume>150</volume>
          <fpage>956</fpage>
          <lpage>967</lpage>
          <pub-id pub-id-type="pmid">26764184</pub-id>
        </element-citation>
      </ref>
      <ref id="B73">
        <label>73</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Ko</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Yi</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Yoo</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Je</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Suh</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>YK</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells</article-title>
          <source>Sci Rep</source>
          <year>2017</year>
          <volume>7</volume>
          <fpage>3710</fpage>
          <pub-id pub-id-type="pmid">28623272</pub-id>
        </element-citation>
      </ref>
      <ref id="B74">
        <label>74</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Momen-Heravi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Saha</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kodys</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Catalano</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Satishchandran</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Szabo</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis</article-title>
          <source>J Transl Med</source>
          <year>2015</year>
          <volume>13</volume>
          <fpage>261</fpage>
          <pub-id pub-id-type="pmid">26264599</pub-id>
        </element-citation>
      </ref>
      <ref id="B75">
        <label>75</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Momen-Heravi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bala</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kodys</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Szabo</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Exosomes derived from alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and sensitize monocytes to LPS</article-title>
          <source>Sci Rep</source>
          <year>2015</year>
          <volume>5</volume>
          <fpage>9991</fpage>
          <pub-id pub-id-type="pmid">25973575</pub-id>
        </element-citation>
      </ref>
      <ref id="B76">
        <label>76</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Devhare</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Sasaki</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Shrivastava</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Di Bisceglie</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Ray</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ray</surname>
              <given-names>RB</given-names>
            </name>
          </person-group>
          <article-title>Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells</article-title>
          <source>J Virol</source>
          <year>2017</year>
          <fpage>91</fpage>
        </element-citation>
      </ref>
      <ref id="B77">
        <label>77</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bukong</surname>
              <given-names>TN</given-names>
            </name>
            <name>
              <surname>Momen-Heravi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kodys</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bala</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Szabo</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90</article-title>
          <source>PLoS Pathog</source>
          <year>2014</year>
          <volume>10</volume>
          <fpage>e1004424</fpage>
          <pub-id pub-id-type="pmid">25275643</pub-id>
        </element-citation>
      </ref>
      <ref id="B78">
        <label>78</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seo</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Eun</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Yi</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Jang</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Jo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>YM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Exosome-mediated activation of toll-like receptor 3 in stellate cells stimulates interleukin-17 production by &#x3B3;&#x3B4; T cells in liver fibrosis</article-title>
          <source>Hepatology</source>
          <year>2016</year>
          <volume>64</volume>
          <fpage>616</fpage>
          <lpage>631</lpage>
          <pub-id pub-id-type="pmid">27178735</pub-id>
        </element-citation>
      </ref>
      <ref id="B79">
        <label>79</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Charrier</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kemper</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hattori</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takigawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brigstock</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Exosomes mediate intercellular transfer of pro-fibrogenic connective tissue growth factor (CCN2) between hepatic stellate cells, the principal fibrotic cells in the liver</article-title>
          <source>Surgery</source>
          <year>2014</year>
          <volume>156</volume>
          <fpage>548</fpage>
          <lpage>555</lpage>
          <pub-id pub-id-type="pmid">24882759</pub-id>
        </element-citation>
      </ref>
      <ref id="B80">
        <label>80</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kemper</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Charrier</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brigstock</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Suppression of fibrogenic signaling in hepatic stellate cells by Twist1-dependent microRNA-214 expression: Role of exosomes in horizontal transfer of Twist1</article-title>
          <source>Am J Physiol Gastrointest Liver Physiol</source>
          <year>2015</year>
          <volume>309</volume>
          <fpage>G491</fpage>
          <lpage>G499</lpage>
          <pub-id pub-id-type="pmid">26229009</pub-id>
        </element-citation>
      </ref>
      <ref id="B81">
        <label>81</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Velazquez</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Brigstock</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Fibrogenic Signaling Is Suppressed in Hepatic Stellate Cells through Targeting of Connective Tissue Growth Factor (CCN2) by Cellular or Exosomal MicroRNA-199a-5p</article-title>
          <source>Am J Pathol</source>
          <year>2016</year>
          <volume>186</volume>
          <fpage>2921</fpage>
          <lpage>2933</lpage>
          <pub-id pub-id-type="pmid">27662798</pub-id>
        </element-citation>
      </ref>
      <ref id="B82">
        <label>82</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>DeLeve</surname>
              <given-names>LD</given-names>
            </name>
          </person-group>
          <article-title>Liver sinusoidal endothelial cells in hepatic fibrosis</article-title>
          <source>Hepatology</source>
          <year>2015</year>
          <volume>61</volume>
          <fpage>1740</fpage>
          <lpage>1746</lpage>
          <pub-id pub-id-type="pmid">25131509</pub-id>
        </element-citation>
      </ref>
      <ref id="B83">
        <label>83</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Yaqoob</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>de Assuncao</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>VK</given-names>
            </name>
            <name>
              <surname>Hirsova</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mukhopadhyay</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Huebert</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>VH</given-names>
            </name>
          </person-group>
          <article-title>Exosome Adherence and Internalization by Hepatic Stellate Cells Triggers Sphingosine 1-Phosphate-dependent Migration</article-title>
          <source>J Biol Chem</source>
          <year>2015</year>
          <volume>290</volume>
          <fpage>30684</fpage>
          <lpage>30696</lpage>
          <pub-id pub-id-type="pmid">26534962</pub-id>
        </element-citation>
      </ref>
      <ref id="B84">
        <label>84</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ichinohe</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tanimizu</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kon</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yoshioka</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ochiya</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mizuguchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hirata</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mitaka</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Transplantation of Thy1+ Cells Accelerates Liver Regeneration by Enhancing the Growth of Small Hepatocyte-Like Progenitor Cells via IL17RB Signaling</article-title>
          <source>Stem Cells</source>
          <year>2017</year>
          <volume>35</volume>
          <fpage>920</fpage>
          <lpage>931</lpage>
          <pub-id pub-id-type="pmid">27925343</pub-id>
        </element-citation>
      </ref>
      <ref id="B85">
        <label>85</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Brigstock</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Integrins and heparan sulfate proteoglycans on hepatic stellate cells (HSC) are novel receptors for HSC-derived exosomes</article-title>
          <source>FEBS Lett</source>
          <year>2016</year>
          <volume>590</volume>
          <fpage>4263</fpage>
          <lpage>4274</lpage>
          <pub-id pub-id-type="pmid">27714787</pub-id>
        </element-citation>
      </ref>
      <ref id="B86">
        <label>86</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fiore</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Malvicini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bayo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Peixoto</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Atorrasagasti</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sierra</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rodr&#xED;guez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>G&#xF3;mez Bustillo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Garc&#xED;a</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Aquino</surname>
              <given-names>JB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Involvement of hepatic macrophages in the antifibrotic effect of IGF-I-overexpressing mesenchymal stromal cells</article-title>
          <source>Stem Cell Res Ther</source>
          <year>2016</year>
          <volume>7</volume>
          <fpage>172</fpage>
          <pub-id pub-id-type="pmid">27876093</pub-id>
        </element-citation>
      </ref>
      <ref id="B87">
        <label>87</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramachandran</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Iredale</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Macrophages: central regulators of hepatic fibrogenesis and fibrosis resolution</article-title>
          <source>J Hepatol</source>
          <year>2012</year>
          <volume>56</volume>
          <fpage>1417</fpage>
          <lpage>1419</lpage>
          <pub-id pub-id-type="pmid">22314426</pub-id>
        </element-citation>
      </ref>
      <ref id="B88">
        <label>88</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saha</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Momen-Heravi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Furi</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kodys</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Catalano</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gangopadhyay</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Haraszti</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Satishchandran</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Iracheta-Vellve</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Adejumo</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Extracellular vesicles from mice with alcoholic liver disease carry a distinct protein cargo and induce macrophage activation through heat shock protein 90</article-title>
          <source>Hepatology</source>
          <year>2018</year>
          <volume>67</volume>
          <fpage>1986</fpage>
          <lpage>2000</lpage>
          <pub-id pub-id-type="pmid">29251792</pub-id>
        </element-citation>
      </ref>
      <ref id="B89">
        <label>89</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Verma</surname>
              <given-names>VK</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hirsova</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mushref</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Contreras</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Malhi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kamath</surname>
              <given-names>PS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles</article-title>
          <source>J Hepatol</source>
          <year>2016</year>
          <volume>64</volume>
          <fpage>651</fpage>
          <lpage>660</lpage>
          <pub-id pub-id-type="pmid">26632633</pub-id>
        </element-citation>
      </ref>
      <ref id="B90">
        <label>90</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saha</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Momen-Heravi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kodys</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Szabo</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>MicroRNA Cargo of Extracellular Vesicles from Alcohol-exposed Monocytes Signals Naive Monocytes to Differentiate into M2 Macrophages</article-title>
          <source>J Biol Chem</source>
          <year>2016</year>
          <volume>291</volume>
          <fpage>149</fpage>
          <lpage>159</lpage>
          <pub-id pub-id-type="pmid">26527689</pub-id>
        </element-citation>
      </ref>
      <ref id="B91">
        <label>91</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saha</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bruneau</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Kodys</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Szabo</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Alcohol-induced miR-27a regulates differentiation and M2 macrophage polarization of normal human monocytes</article-title>
          <source>J Immunol</source>
          <year>2015</year>
          <volume>194</volume>
          <fpage>3079</fpage>
          <lpage>3087</lpage>
          <pub-id pub-id-type="pmid">25716995</pub-id>
        </element-citation>
      </ref>
      <ref id="B92">
        <label>92</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>OK</given-names>
            </name>
          </person-group>
          <article-title>Exosomes from mesenchymal stem cells induce the conversion of hepatocytes into progenitor oval cells</article-title>
          <source>Stem Cell Res Ther</source>
          <year>2017</year>
          <volume>8</volume>
          <fpage>117</fpage>
          <pub-id pub-id-type="pmid">28535778</pub-id>
        </element-citation>
      </ref>
      <ref id="B93">
        <label>93</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Du</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Exosomes from Human-Induced Pluripotent Stem Cell-Derived Mesenchymal Stromal Cells (hiPSC-MSCs) Protect Liver against Hepatic Ischemia/ Reperfusion Injury via Activating Sphingosine Kinase and Sphingosine-1-Phosphate Signaling Pathway</article-title>
          <source>Cell Physiol Biochem</source>
          <year>2017</year>
          <volume>43</volume>
          <fpage>611</fpage>
          <lpage>625</lpage>
          <pub-id pub-id-type="pmid">28934733</pub-id>
        </element-citation>
      </ref>
      <ref id="B94">
        <label>94</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bruno</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Grange</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Deregibus</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Calogero</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Saviozzi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Collino</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Morando</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Busca</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Falda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bussolati</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mesenchymal stem cell-derived microvesicles protect against acute tubular injury</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2009</year>
          <volume>20</volume>
          <fpage>1053</fpage>
          <lpage>1067</lpage>
          <pub-id pub-id-type="pmid">19389847</pub-id>
        </element-citation>
      </ref>
      <ref id="B95">
        <label>95</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akyurekli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Le</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Richardson</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Fergusson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Tay</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Allan</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
          <article-title>A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles</article-title>
          <source>Stem Cell Rev</source>
          <year>2015</year>
          <volume>11</volume>
          <fpage>150</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="pmid">25091427</pub-id>
        </element-citation>
      </ref>
      <ref id="B96">
        <label>96</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Qian</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis</article-title>
          <source>Stem Cells Dev</source>
          <year>2013</year>
          <volume>22</volume>
          <fpage>845</fpage>
          <lpage>854</lpage>
          <pub-id pub-id-type="pmid">23002959</pub-id>
        </element-citation>
      </ref>
      <ref id="B97">
        <label>97</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Xiang</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Xiang</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Exosomes derived from human menstrual blood-derived stem cells alleviate fulminant hepatic failure</article-title>
          <source>Stem Cell Res Ther</source>
          <year>2017</year>
          <volume>8</volume>
          <fpage>9</fpage>
          <pub-id pub-id-type="pmid">28115012</pub-id>
        </element-citation>
      </ref>
      <ref id="B98">
        <label>98</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haga</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>IK</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matsuda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Extracellular Vesicles from Bone Marrow-Derived Mesenchymal Stem Cells Improve Survival from Lethal Hepatic Failure in Mice</article-title>
          <source>Stem Cells Transl Med</source>
          <year>2017</year>
          <volume>6</volume>
          <fpage>1262</fpage>
          <lpage>1272</lpage>
          <pub-id pub-id-type="pmid">28213967</pub-id>
        </element-citation>
      </ref>
      <ref id="B99">
        <label>99</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tan</surname>
              <given-names>CY</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Dan</surname>
              <given-names>YY</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>HK</given-names>
            </name>
          </person-group>
          <article-title>Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models</article-title>
          <source>Stem Cell Res Ther</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>76</fpage>
          <pub-id pub-id-type="pmid">24915963</pub-id>
        </element-citation>
      </ref>
      <ref id="B100">
        <label>100</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zou</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mao</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gong</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Qian</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>hucMSC Exosome-Derived GPX1 Is Required for the Recovery of Hepatic Oxidant Injury</article-title>
          <source>Mol Ther</source>
          <year>2017</year>
          <volume>25</volume>
          <fpage>465</fpage>
          <lpage>479</lpage>
          <pub-id pub-id-type="pmid">28089078</pub-id>
        </element-citation>
      </ref>
      <ref id="B101">
        <label>101</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nong</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Niu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ai</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Hepatoprotective effect of exosomes from human-induced pluripotent stem cell-derived mesenchymal stromal cells against hepatic ischemia-reperfusion injury in rats</article-title>
          <source>Cytotherapy</source>
          <year>2016</year>
          <volume>18</volume>
          <fpage>1548</fpage>
          <lpage>1559</lpage>
          <pub-id pub-id-type="pmid">27592404</pub-id>
        </element-citation>
      </ref>
      <ref id="B102">
        <label>102</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Armstrong</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Holme</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>Re-Engineering Extracellular Vesicles as Smart Nanoscale Therapeutics</article-title>
          <source>ACS Nano</source>
          <year>2017</year>
          <volume>11</volume>
          <fpage>69</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="pmid">28068069</pub-id>
        </element-citation>
      </ref>
      <ref id="B103">
        <label>103</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dilnawaz</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Acharya</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sahoo</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>Recent trends of nanomedicinal approaches in clinics</article-title>
          <source>Int J Pharm</source>
          <year>2018</year>
          <volume>538</volume>
          <fpage>263</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="pmid">29339248</pub-id>
        </element-citation>
      </ref>
      <ref id="B104">
        <label>104</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lou</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>MiR-122 modification enhances the therapeutic efficacy of adipose tissue-derived mesenchymal stem cells against liver fibrosis</article-title>
          <source>J Cell Mol Med</source>
          <year>2017</year>
          <volume>21</volume>
          <fpage>2963</fpage>
          <lpage>2973</lpage>
          <pub-id pub-id-type="pmid">28544786</pub-id>
        </element-citation>
      </ref>
      <ref id="B105">
        <label>105</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zeng</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zhuang</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Identification of a novel TGF-&#x3B2;-miR-122-fibronectin 1/serum response factor signaling cascade and its implication in hepatic fibrogenesis</article-title>
          <source>Oncotarget</source>
          <year>2015</year>
          <volume>6</volume>
          <fpage>12224</fpage>
          <lpage>12233</lpage>
          <pub-id pub-id-type="pmid">25909171</pub-id>
        </element-citation>
      </ref>
      <ref id="B106">
        <label>106</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Exosomes derived from miR-181-5p-modified adipose-derived mesenchymal stem cells prevent liver fibrosis via autophagy activation</article-title>
          <source>J Cell Mol Med</source>
          <year>2017</year>
          <volume>21</volume>
          <fpage>2491</fpage>
          <lpage>2502</lpage>
          <pub-id pub-id-type="pmid">28382720</pub-id>
        </element-citation>
      </ref>
      <ref id="B107">
        <label>107</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>FB</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>DZ</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>XY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>BMSCs-derived miR-223-containing exosomes contribute to liver protection in experimental autoimmune hepatitis</article-title>
          <source>Mol Immunol</source>
          <year>2018</year>
          <volume>93</volume>
          <fpage>38</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="pmid">29145157</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>